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Early life heart rate (HR) and heart rate variability (HRV) reflect autonomic maturation. 
Intervention with n-3 long chain polyunsaturated fatty acids (LCPUFAs) during pregnancy 
favorably affects fetal HR and HRV; similar observations have been reported with infant n-3 
LCPUFA intake. Infant HR and HRV have not been assessed in relation to maternal fatty acid 
status during pregnancy. Further, exposure to intrauterine inflammation may underlie these 
observations, although this hypothesis has not been tested. The aim of this observational study 
was to explore associations between maternal fatty acid and inflammatory status during 
pregnancy and infant HR and HRV. Simple linear and multiple regression were used to describe 
relationships for infant HR and HRV at 2 weeks, 4 months, and 6 months of age and: 1) maternal 
erythrocyte n-6 and n-3 fatty acids, 2) maternal plasma n-6 and n-3 endocannabinoids, and 3) 
maternal serum cytokines (interleukin-6, tumor necrosis factor-α), adipokine (adiponectin), and 
acute phase reactant (C-reactive protein) at 20, 24, 32, and 36 gestational weeks. Higher maternal 
n-3 fatty acid status, especially DHA, during pregnancy was inversely related to infant HR and 
positively related to HRV; the inverse was observed for n-6 fatty acids. Maternal n-3 
endocannabinoids during pregnancy were inversely related with infant HR and positively related 
to infant HRV. Conversely, when the n-6:n-3 endocannabinoid ratio more heavily favored the n-
6 endocannabinoid series, there was a positive and inverse association with infant HR and HRV, 
respectively. Limited associations between the other inflammatory biomarkers (interleukin-6, 
tumor necrosis factor-α, adiponectin, C-reactive protein) and infant HR/HRV were observed. As 
such, we cannot definitively conclude there is a link between intrauterine exposure to these 
biomarkers and infant autonomic development. These data build on existing literature evidencing 
a role for n-3 fatty acids in accelerating fetal and infant autonomic development and may 
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indicate an anti-inflammatory role for n-3 endocannabinoids. This study is the first to examine 
potential relationships between maternal fatty acid status, maternal inflammation, and infant 
autonomic development. Further, this study is the first to examine endocannabinoids in relation 
to HR and HRV in any population.
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CHAPTER 1. LITERATURE REVIEW 
1.1 Biological significance of essential fatty acids 
1.1.1 Fatty acid characteristics 
 Fatty acids are hydrocarbon chains varying in length from 2 to 30-plus carbons with a 
methyl group at one end of the chain and a carboxyl group at the other. Structurally, fatty acids 
differ in number, type, and position of double bonds, as well as chain length. The molecular 
structure of various fatty acid classes is depicted in Figure 1.1.  
Stearic acid, an example of a saturated fatty acid, contains 18 carbons and no double 
bonds. The term “saturated” refers to the hydrogen molecules, as all carbons in the chain, 
excepting that in the carboxyl group, are linked to as many hydrogen atoms as possible. Fatty 
acids with at least one double bond between adjacent carbon atoms are “unsaturated”. Degree of 
unsaturation varies; fatty acids with only one double bond are monounsaturated fatty acids, while 
fatty acids with two or more double bonds are polyunsaturated fatty acids (PUFA). Double bonds 
can exist in cis- or trans- conformation and may occur in different positions within the 
hydrocarbon chain, as demonstrated in Figure 1.1.  
Double bonds (=) are counted from the methyl end (CH3) of the molecule and denoted by n-x 
or ω-x, where n- or ω- denotes the terminal carbon and x is the position of the first double 
bond. 
 
Stearic acid (18:0) 
CH3-(CH2)16-COOH 
 
Oleic acid (18:1n-9) 
CH3-(CH2)7-CH=CH-(CH2)7-COOH 
 
Linoleic acid (18:2n-6) 
CH3-(CH2)4-CH=CH-CH2-CH=CH-(CH2)7-COOH 
 
Linolenic acid (18:3n-3) 
CH3-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-(CH2)7-COOH 
Figure 1.1 Molecular structure and nomenclature of fatty acids 
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1.1.2 Fatty acid nomenclature 
In naming unsaturated fatty acids as a biologist, double bonds are counted from the 
methyl end of the molecule and are denoted by “n-x” or “ω-x”, where “x” is the position of the 
double bond and “n-” or “ω-” represents the terminal carbon, or the methyl end. For example, 
stearic acid, a saturated fatty acid, is designated as 18:0, as it contains 18 carbons and no double 
bonds. Oleic acid, a monounsaturated fatty acid containing 18 carbons, is denoted as 18:1n-9 or 
18:1ω-9, with “1” indicating the presence of a single double bond and “n-9” or “ω-9” indicating 
where the double bond occurs, between carbon 9 and 10 from the terminal methyl, in this case.  
A fatty acid containing 18 carbons and 3 double bonds with the first double bond 
occurring between the third and fourth carbons from the terminal methyl would be written as 
18:3n-3 or 18:3ω-3 and termed an “n-3” fatty acid. Conversely, a fatty acid with two double 
bonds, the first of which occurs between the sixth and seventh carbons from the methyl end, 
would be written as 18:2n-6, and termed an “n-6” fatty acid.  
1.1.3 Essential fatty acids 
 Most fatty acids can be synthesized de novo; however, human and mammalian cells lack 
enzymes required to synthesize linoleic acid (LA), the n-6 series precursor, and α-linolenic acid 
(α-LA), the n-3 series precursor (Simopoulos, 2002a). Therefore, these fatty acids must be 
obtained through the diet and are, therefore, “essential fatty acids” for humans. 
Essential fatty acids are ubiquitous components of cell membranes and dictate membrane 
fluidity and membrane-bound enzyme/receptor activity. Essential fatty acids have various 
functions in the body; most of these functions require conversion to eicosanoids or other 
products but the fatty acids themselves can be functionally active (ie., platelet aggregation, 
leukocyte stimulation) and directly influence membrane fluidity (Simopoulos, 2002a). 
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1.1.4 Metabolism of essential fatty acids 
The n-3 and n-6 fatty acid families share an enzymatic pathway and are metabolically 
competitive (reviewed by Simopoulos, 2002a). LA (18:2n-6) is converted to γ-LA (18:3n-6) by 
Δ6 desaturase, then elongated to form dihomo-γ-LA (DGLA; 20:3n-6), which can be converted to 
arachidonic acid (ARA, 20:4n-6) via Δ5 desaturase. In the n-3 series, α-LA (18:3n-3) is converted 
to eicosapentaenoic acid (EPA, 20:5n-3) by a series of Δ5- and Δ6-desaturases and elongase. An 
additional desaturase (Δ4) and elongase converts EPA to docosahexaenoic acid (DHA, 22:6n-3). 
Retroconversion of DHA to EPA can occur with DHA supplementation, albeit at low basal rates 
(Brossard et al., 1996). The preferred substrate for Δ5- and Δ6-desaturases and elongases is α-LA; 
however, in the case of excess dietary LA, shared enzymes are saturated, preventing significant 
conversion of α-LA to longer chain n-3 metabolites (Kris-Etherton et al., 2000). Clinically, less 
than 8% of dietary α-LA is metabolized to EPA while conversion rate of α-LA to DHA is even 
lower, 0.02 – 4% (Burdge et al., 2002).  
Dietary essential fatty acid deficiency is uncommon in developed countries. Optimal LA 
to α-LA intake is estimated to be 4:1, but dietary intake in Western countries approaches or 
exceeds 15:1, reflecting consumption of LA-rich vegetable oils (Wall et al., 2010) and a negative 
net effect on α-LA conversion. Therefore, intake of preformed α-LA and the longer chain 
metabolites EPA and DHA, known as n-3 long chain polyunsaturated fatty acids (LCPUFA), 
EPA and DHA, is recommended. 
1.1.5 Dietary sources of n-3 LCPUFA 
The primary dietary sources of EPA and DHA, along with their respective n-3 LCPUFA 
content per serving, are listed in Table 1.1. In general, deep water fish from colder temperatures 
(tuna, salmon, mackerel) have the highest content of EPA and DHA. As demonstrated in Table 
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1.1, fatty acid content and profile varies considerably according to fish species, geographical 
location, and method of harvesting/farming. As such, reported fatty acid content should be taken 









# 4 oz. servings to 
provide 250 mg 
 n-3 LCPUFA3 
Oz. to provide 250 mg 
n-3 LCPUFA 
Bass     
   Sea 492 183 0.37 1.48 
   Striped 663 192 0.29 1.17 
Catfish     
   Farmed 64 19 3.02 12.10 
   Wild 265 147 0.61 2.43 
Cod     
   Atlantic 136 72 1.20 4.81 
   Pacific 109 39 1.69 6.76 
Herring     
   Atlantic 977 804 0.14 0.56 
   Pacific 781 1099 0.13 0.53 
Flounder 123 155 0.90 3.61 
Salmon     
   Atlantic, farmed 1251 977 0.11 0.45 
   Atlantic, wild 1264 364 0.15 0.61 
   Pink 377 207 0.43 1.71 
   Sockeye 1797 395 0.11 0.46 
Tilapia 97 5 2.44 9.74 
Trout 599 229 0.30 1.21 
Tuna     
   Bluefin 1009 321 0.19 0.75 
   Light, canned in water 223 32 0.98 3.93 
   Yellowfin 100 13 2.21 8.82 
   White, canned in water 713 264 0.26 1.02 
1Adapted from the USDA National Nutrient Database for Standard Reference, Release 28 and Drewery et al., 2016; 
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LCPUFA = long chain polyunsaturated fatty acid 
2Nutrient values are estimates and depend on species of fish, total fat content of fish, geographical location, method of 
raising/harvesting, and cooking. All values are for raw portions. 
3# of servings (4 oz.) were calculated to meet 250 mg of n-3 LCPUFA per day, as recommended for pregnant women 
by the Dietary Guidelines for Americans (2015-2020). 
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1.1.6 PUFA status and inflammation 
 Inflammation is an immunological response of tissue to injury or infection. The 
inflammatory response is a normal, protective mechanism to remove harmful stimuli and initiate 
the healing process. However, persistent or excessive inflammation can lead to development of 
acute and chronic diseases characterized by production of cytokines, eicosanoids, and other 
inflammatory factors.  
Inflammation and PUFA status are biologically interrelated. Essential fatty acids are 
precursors of eicosanoids, and these modulate the intensity and duration of an inflammatory 
response, dictating overall pathophysiological outcome (reviewed by Calder, 2006). Eicosanoids 
derived from 20-carbon PUFAs (DGLA, ARA, EPA) include prostaglandins, thromboxanes, 
leukotrienes, hydroperoxyeicosatetraenoic acids (HPETE), and hydroxyeicosatetraenoic acids 
(HETE).  
In response to inflammation, phospholipase A2 releases a 20-carbon fatty acid from the 
lipid pool within the cell membrane. The fatty acid is converted to an eicosanoid by 
cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome P450 enzymes; COX enzymes 
produce prostaglandins and thromboxanes, LOX enzymes produce leukotrienes, and cytochrome 
P450 enzymes produce HPETE and HETE (reviewed by Calder, 2013). There are two isoforms 
of the COX enzyme; COX-1 is a constitutive enzyme and COX-2 is specific to immune cells. 
While the same COX and LOX pathways metabolize each 20-carbon PUFA, the eicosanoids 
produced from each PUFA precursor vary in potency and differ structurally and physiologically 





1.1.7 Inflammatory events directed by PUFA 
Pro-inflammatory events are initiated and exacerbated by eicosanoids derived from ARA, 
whereas equivalent products from EPA tend to nullify and reverse the inflammatory response. 
The 2 series of prostaglandins and thromboxanes (PGE2, PGF2, PGD2, and TXA2) are 
synthesized from ARA by the COX pathway. These prostaglandins have various physiological 
effects, including increased vascular permeability, vascular dilation, neutrophil chemotaxis, and 
stimulation of smooth muscle cell migration and proliferation (Richard et al., 2000). The 2-series 
of thromboxanes are involved in platelet aggregation and blood vessel constriction (Sellers and 
Stallone, 2008). Metabolism of ARA by 5-LOX produces hydroxy- and hydroperoxy-derivatives 
(5-HETE and 5-HPETE) and the 4-series of leukotrienes (LTC4, LTB4, LTD4, and LTE4). These 
leukotrienes are involved in induction of smooth-muscle contraction and act as chemoattractants 
of neutrophils (Peters-Golden et al., 2005).  
 The n-3 derived prostaglandins (PGD3, PGF3, and PGE3), thromboxanes (TXA3), and 
leukotrienes (LTB5, LTC5, LTD5, and LTE5) have weaker bioactivity than their respective n-6 
derived metabolites (reviewed by Calder, 2006). For example, LTB5 is 10- to 100-fold less 
potent as a neutrophil chemoattractant than LTB4 (Goldman et al., 1983; Lee et al., 1984b). 
Similarly, PGE2 stimulates COX-2 in fibroblasts, up-regulating its own production and inducing 
pro-inflammatory cytokine production by macrophages; EPA-derived PGE3 is a less potent 
inducer of these pathways (Bagga et al., 2003).  
Biological activity and potency is related to affinity of cellular eicosanoid receptors. 
These receptors have greater affinity for n-6 derived eicosanoids than those derived from n-3. 
Thus, collective actions of n-3 produced eicosanoids are weak (Wada et al., 2007). 
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The type and amount of PUFA released in response to inflammatory stimuli depends on 
fatty acid content of the cell membrane phospholipid pool. When cell membranes contain large 
amounts of ARA relative to DGLA or EPA, which characterizes a typical Western diet, ARA is 
the primary substrate for eicosanoid synthesis (reviewed by Calder, 2006). Eicosanoids from n-6 
are biologically active in small quantities and play an important modulatory role in the immune 
response by stimulating leukocytes (reviewed by Simopoulos, 2002b). However, if ARA-derived 
eicosanoids are present in large quantities, damage to host tissues can ensue and contribute to 
inflammatory disorders (Kinsella et al., 1990).  
Supplementation with fish oil, a source of EPA and DHA, displaces ARA from cell 
membrane phospholipid pools, modulating the inflammatory response. This occurs especially in 
membranes of erythrocytes, neutrophils, monocytes, and liver cells (reviewed by Simopoulos, 
2003; reviewed by Calder, 2006). In addition to competing for metabolic enzymes, EPA also 
competes with ARA for active sites of COX- and LOX-enzymes, suppressing generation of n-6 
derived eicosanoids, further dampening the ARA-mediated pro-inflammatory response (James et 
al., 2000; reviewed by Calder, 2006).  
Increased fish oil intake and subsequent EPA-induced suppression of n-6 derived 
eicosanoids is reflected in an elevation of n-3 derived eicosanoids. Fish oil supplementation 
decreases inflammatory cell production of PGE2, LTB4, TXB2, LTE4, and 5-HETE while 
increasing production of the less inflammatory LTB4, LTE5, and 5-HEPE (Sperling et al., 1993; 
von Schacky et al., 1993; Caughey et al., 1996).  
Potent anti-inflammatory mediators, resolvins and protectins, are also generated from 
EPA and DHA (Serhan et al., 2008). The E-series resolvins are generated from EPA and the D-
series resolvins, docosatrienes and neuroprotectins, are generated from DHA by COX-2 and 
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LOX-initiated pathways (Serhan et al., 2002). Both the D- and E-series of resolvins exert anti-
inflammatory and immunoregulatory actions, including suppression of neutrophil chemotaxis, 
regulation of cytokines, and elimination of endothelial production of reactive oxygen species 
(Serhan et al., 2000; Serhan et al., 2002; Hong et al., 2003; Mukherjee et al., 2004). 
Anti-inflammatory actions of n-3 LCPUFA are not strictly eicosanoid-dependent. Fish oil 
supplementation also reduces generation of pro-inflammatory cytokines (Lo et al., 1999; Zhao et 
al., 2004; Bhattacharya et al., 2006) by altering inflammatory gene expression via transcription 
factors, nuclear factor kappa B (NFκB) and peroxisome proliferator-activated receptors (PPARs) 
(reviewed by Calder, 2002; reviewed by Calder, 2006). NFκB is involved in up-regulation of 
several cytokines and enzymes implicated in the pathogenesis of chronic inflammatory diseases. 
In its inactive form, NFκB is a cytosolic trimer. Once activated by extracellular inflammatory 
stimuli, the inhibitory subunit (IκB) is phosphorylated and dissociates, allowing the remaining 
NFκB dimer to translocate to the nucleus and bind motifs in the promoter regions of pro-
inflammatory genes (Hayden et al., 2006; Perkins, 2007). 
There are several mechanisms by which n-3 LCPUFA interfere with NFκB activation: i) 
induction and activation of PPARγ, which physically blocks NFκB nuclear translocation; ii) 
disruption of membrane lipid rafts that initiate inflammatory signaling and activate NFκB; and 
iii) promotion of a cell surface G-protein coupled receptor which initiates an anti-inflammatory 
signaling cascade and inhibits signaling of NFκB activation (Lee et al., 2001; Van den Berghe et 
al., 2003; Oh et al., 2010).  
Although infection resolution depends on cytokines, over-production has implications in 
pathological responses which can lead to inflammation. Specifically, cytokines induce fever, 
activate B- and T-lymphocytes, and regulate the acute phase response (reviewed by Simopoulos, 
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2002b). Cytokines with relevancy in inflammation are the interleukins (IL), especially IL-1, IL-
6, IL-1β, and tumor necrosis factor (TNF)-α.  
Clinically, DHA and EPA supplementation has been documented to decrease production 
of pro-inflammatory cytokines (Meydani et al., 1991; Endres et al., 1993; Gallai et al., 1993; 
Caughey et al., 1996), while null effects have also been reported (Yaqoob et al., 2000; Schmidt 
et al., 2010). Decreased production of pro-inflammatory cytokines translates to interest in n-3 
LCPUFA as therapeutic agents in chronic inflammatory diseases, including rheumatoid arthritis, 
asthma, and inflammatory bowel disease. Evidence for the effectiveness of n-3 LCPUFA in 
improving clinical conditions and biochemical factors of these diseases has been reviewed 
(Simopoulos et al., 2002b). Overall, significant benefits are associated with n-3 LCPUFA 
supplementation, including decreased disease activity and lowered use of anti-inflammatory 
drugs (Simopoulos et al., 2002b). These observations underline the importance of incorporating 
DHA and EPA in the diet and shifting essential fatty acid intake (LA:α-LA) to favor the n-3 
series. 
1.2 Metabolic status and pregnancy as a state of inflammation 
 
1.2.1 Inflammation as a natural state during pregnancy 
 
 Pregnancy is a natural state of inflammation characterized by distinct physiological 
changes (Sacks et al., 2004). In early pregnancy, maternal pancreatic β-cells undergo 
hyperplasia, resulting in increased insulin secretion and heightened insulin sensitivity (reviewed 
by Butte, 2000). As gestational age advances, secretion of diabetogenic hormones, including 
human placental lactogen, growth hormone, cortisol, and progesterone, markedly reduce insulin 
sensitivity by interfering with insulin receptor signaling at peripheral tissues (Newbern and 
Freemark, 2011). As insulin becomes less effective at suppressing lipid catabolism, there is a 
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shift from lipogenesis, which promotes accumulation of maternal fat stores in early and mid-
pregnancy, to lipolysis in late pregnancy (Elliot, 1975; reviewed by Butte, 2000). 
Cytokine production further stimulates lipolysis and inhibits lipoprotein lipase activity, 
with a net result of adipose tissue mobilization (Feingold and Grunfield, 1992). Maternal 
hyperlipidemia occurs and basal circulating triglyceride and cholesterol concentrations increase 
2- to 3-fold (Knopp et al., 1980). Together, these hormonal alterations and hyperlipidemia result 
in a state of insulin resistance that peaks during the third trimester (Catalano et al., 1991).  
Women with normal glucose tolerance prior to pregnancy have 50 – 70% decreased 
insulin sensitivity by the third trimester (Catalono et al., 1991; reviewed by Butte, 2000). 
Further, during the third trimester, lipoprotein lipase activity is redistributed from maternal 
tissues to the placenta, increasing placental capacity for fatty acid uptake (Herrera et al., 1988; 
reviewed by Haggarty, 2004). The progression of a normal pregnancy depends on these 
processes as they: i) provide an energy source for maternal needs in late gestation, ii) support 
enhanced nutrient transport across the placenta to the fetus, and iii) ensure a continuous supply of 
nutrients to the fetus despite intermittent maternal food intake (Swislocki and Kraemer, 1989; 
reviewed by Butte, 2000). The mother is able to preferentially use fat for fuel, preserving 
available glucose and amino acids for the fetus and minimizing protein catabolism (reviewed by 
Butte, 2000; Soma-Pillay et al., 2016). These physiological responses coincide with a time of 
significant energy demands from the mother and fetus. Maternal energy needs are greatest during 
the third trimester (reviewed by Catalano, 2010) and 90% of fetal fat deposition occurs after 30 
weeks of gestation (reviewed by Haggarty, 2002). 
 Beyond the effects on maternal metabolism, physiological changes during pregnancy also 
prevent rejection of the placenta/fetus and are necessary for delivery (reviewed by Challis et al., 
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2009). With advancing gestational age, inflammatory responsiveness increases. Pro-
inflammatory cytokines actively remodel the cervix which weakens until fetal membranes 
rupture, activating uterine contractions (Young et al., 2002; Osman et al., 2003; King et al., 
2007). T lymphocytes regulate this immunological response by producing cytokines. T 
lymphocytes can be divided into two functional groups that produce different cytokines: i) Th1, 
which promote cell-mediated immune responses, and ii) Th2, which are involved in humoral 
immunity (reviewed by Challis et al., 2009). The major sites of Th2 cytokine production are non-
lymphoid tissues, including placental and decidual tissues (Chaouat, 1999). During normal 
pregnancy, the balance of Th1/Th2 activity is shifted to Th2, which plays a protective role in the 
feto-maternal relationship (reviewed by Challis et al., 2009).  
1.2.2 Exaggerated response to excess maternal weight 
 In the United States, over two-thirds of women of reproductive ages have a body mass 
index (BMI) classified as overweight or obese (≥25.0 kg/m2; Flegal et al., 2010). Maternal 
overweight and obesity are associated with increased risk of adverse obstetric outcome(s); 
antenatal risks include gestational diabetes and hypertension (Sebire et al., 2001; Bhattacharya et 
al., 2007; Denison et al., 2008) while peripartal risks include induction of labor and unplanned 
operative delivery (Sebire et al., 2001; Denison et al., 2008; Galán et al., 2011).  
Heightened inflammation, which accompanies excess maternal weight, alters the 
Th1/Th2 balance, causing a shift to Th1 predominance (reviewed by Challis et al., 2009). This 
shift initiates and intensifies the cascade of pro-inflammatory cytokine production implicated in 
spontaneous abortion, preterm delivery, and gestational diabetes mellitus (reviewed by Challis et 
al., 2009). Compared to normal weight pregnant women, obese pregnant women have elevated 
circulating levels of pro-inflammatory cytokines (Challier et al., 2008; reviewed by Catalano et 
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al., 2009; Basu et al., 2011; Roberts et al., 2011; Aye et al., 2014), including TNF-α and IL-6, 
both of which are implicated in insulin resistance (Borst, 2004; Kershaw and Flier, 2004). The 
source of these cytokines are likely T lymphocytes (reviewed by Challis et al., 2009), maternal 
adipose tissue (Denison et al., 2010; Aye et al., 2014), and the placenta (Denison et al., 2010). 
Adipose tissue is an endocrine organ and a significant source of cytokines (Kershaw and 
Flier, 2004). Table 1.2 outlines pro-inflammatory cytokines that are expressed and secreted by 
adipose tissue and the effects of obesity on that expression. Obesity is defined by massive 
expansion of adipose tissue. mRNA expression of monocyte chemoattractant protein (MCP)-1 
and TNF-α, pro-inflammatory molecules, is increased 2- to 5-fold in adipose tissue and placenta 
of obese pregnant women as compared to normal weight pregnant women (Basu et al, 2011; 
Roberts et al., 2011). Further, macrophages infiltrate adipose tissue of obese pregnant women 
(Denison et al., 2010).  
The placenta can be described as an inflammatory organ. Obese pregnant women have a 
2- to 3-fold increase in placental macrophages compared to normal weight or overweight women 
(Challier et al., 2008). Further, these macrophages are associated with increased expression of 
pro-inflammatory cytokines (Challier et al., 2008). These findings are consistent with animal 
studies which highlight a difference in placental production of inflammatory markers 
(carboxypeptidase E and resistin) between obese and non-obese pregnant populations (Singh et 
al., 2006; Zhou et al., 2006). It has also been reported that obese pregnant women have increased 
placental mRNA expression of IL-1β, IL-8, MCP-1, and CXCR2 (IL-8 receptor) versus normal 
weight pregnant women (Roberts et al., 2011). Overall, these findings support a role of the 
placenta in inflammation and indicate an up-regulation of placental inflammatory activities 
associated with maternal overweight and/or obesity. 
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Table 1.2 Pro-inflammatory factors expressed and secreted by adipose tissue 
Factor1 Obesity-induced changes Functional effect(s) Reference 
TNF-α Increased circulating Downregulates anti-inflammatory 
pathway 
Stimulates lipolysis 
Increases insulin resistance 
Kern et al., 2001 
Cartier et al., 2008 
MCP-1 Increased expression Promotes monocyte recruitment Christiansen et al., 2005 
Di Gregorio et al., 2005 
IL-6 Increased circulating Increases hepatic insulin resistance Kern et al., 2001 
IL-8 Increased circulating Acts as a potent chemoattractant Straczkowski et al., 2002 
IL-1β Increased expression Impairs insulin signaling Juge-Aubry et al., 2003 
1TNF-α: tumor necrosis factor α; MCP-1: monocyte chemoattractant protein; IL: interleukin  
 
Obesity, especially when visceral in nature, is associated with glucose intolerance and 
insulin resistance (Ramsay et al., 2002). Greater abdominal visceral adiposity in the first 
trimester is associated with a positive glucose challenge test between 24 and 28 gestational 
weeks (Martin et al., 2009). Thus, women entering pregnancy with excess weight or gain 
significant weight during pregnancy have increased susceptibility to developing gestational 
diabetes mellitus compared to women who enter pregnancy with a normal BMI (Denison et al., 
2010).  
While increased susceptibility to gestational diabetes mellitus could be attributed to 
exaggerated pro-inflammatory cytokine production, it has been estimated that C-reactive protein 
(CRP) concentrations, an acute phase protein synthesized in response to pro-inflammatory 
cytokines (Sheldon et al., 1993), and circulating triglycerides explain only 30% of the risk of 
increased BMI on gestational hypertension (Bodnar et al., 2005). Colomiere et al. (2009) 
reported defects in the insulin signaling cascade in adipose tissue and skeletal muscle of pregnant 
obese women with normal glucose tolerance. This report points to another factor which may 
contribute to susceptibility of obese women to gestational diabetes mellitus. These observations 
(Challier et al., 2008; Denison et al., 2010; Basu et al., 2011) suggest that T lymphocytes, 
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maternal adipose tissue, and the placenta contribute to local inflammation which is exaggerated 
by pregavid overweight/obesity. Thus, exaggerated inflammation during pregnancy may be a 
factor in increased risk of adverse obstetric outcome(s) in overweight and obese pregnant 
women. 
1.2.3 Implications for fetal exposure to inflammation 
Maternal overweight and obesity also pose significant health risks to the infant. Increased 
risk for adverse neonatal outcome, including congenital anomalies, asphyxia, death, and 
hypoglycemia are associated with pre-pregnancy overweight and obesity (Kalk et al., 2009; 
Stothard et al., 2009; Galán et al., 2012; Cresswell et al., 2012). Infants born to overweight and 
obese mothers are more likely to be large for gestational age, macrosomic, and insulin resistant 
(Catalano et al., 2009; Sewell et al., 2006; Yu et al., 2013). There is also an association between 
maternal obesity and increased disease risk in later life for the infant, including impaired 
neurodevelopment, cardiovascular, and/or metabolic diseases (Whitaker, 2004; Boney et al., 
2005; Drake and Reynolds, 2010; Van Lieshout et al. 2011; Khandaker et al., 2012). 
 While maternal insulin resistance ensures redirection of nutrients for fetal growth and 
development, the degree of insulin sensitivity is a governing factor determining optimal fetal 
growth versus adiposity (Boney et al., 2005). The natural state of insulin resistance during 
pregnancy is exaggerated by pregavid obesity (Ramsay et al., 2002; Martin et al., 2009; Denison 
et al., 2010). Further, decreased maternal insulin sensitivity is associated with an increase in 
infant adiposity (Jansson and Powell, 2007) which is likely a result of fetal exposure to over-
nutrition in the form of hyperglycemia and hyperlipidemia.  
Infants born to overweight or obese women with normal glucose tolerance have a 2% 
increase in body fat compared to those born to normal weight women with normal glucose 
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tolerance (Sewell et al., 2006). Thus, inflammation accompanying excess maternal weight 
contributes to infant adiposity independently of maternal insulin resistance. The observation that 
maternal obesity activates placental inflammatory signaling without affecting cytokine levels in 
fetal circulation (Aye et al., 2014) indicates that obesity-related inflammation impacts the fetus 
by altering placental function rather than by direct fetal exposure to elevated concentrations of 
pro-inflammatory cytokines. However, increased IL-6 has been found in the umbilical cord 
plasma of fetuses born to obese versus lean women (Catalano et al., 2009). 
Regardless of the pathway by which it exerts its effects, obesity-related inflammation can 
be mitigated, in part, by altering maternal nutrition. Supplementation of n-3 LCPUFA reduces 
inflammation associated with excess weight (Makhoul et al., 2011), although this has not been 
studied during pregnancy in relation to improving adverse obstetric, fetal, or infant outcome 
associated with pregavid overweight and/or obesity, to the authors’ knowledge. The role of n-3 
LCPUFA in reducing inflammation is covered in Section 1.1, benefits of maternal and/or infant 
n-3 LCPUFA intake during the perinatal period are covered in Section 1.3, and a more in-depth 
discussion of the implications of fetal exposure to inflammation, with specificity to the 
autonomic nervous system, are covered in Section 1.4. 
1.3 n-3 and n-6 LCPUFA in development 
1.3.1 The developing brain  
 Development of the human brain begins shortly after conception with neural tube 
formation. During the embryonic phase, before 7 weeks of gestation, brain structure is defined. 
Functional development occurs during the fetal phase, after 8 weeks of gestation (Fitzgerald and 
Folan-Curran, 2002; Larsen et al., 2011).  
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Neural proliferation and apoptosis occur during the first half of pregnancy. Once neurons 
are formed, they migrate to their final destination (Graaf-Peters and Hadders-Algra, 2006). This 
migratory period is accompanied by neuronal differentiation, encompassing processes including 
dendritic formation, axonal formation, and production of neurotransmitters and synapses. The 
number of cortical neurons peaks at 28 weeks of gestation, then declines by 70% to reach a 
stable number by birth (Rabinowicz et al., 1996).  
Beginning during the third trimester and extending to 18 months of age, the brain 
undergoes exponential growth, increasing 10-fold in size (Dobbing and Sands, 1973). This 
period is characterized by synaptogenesis, myelination, axonal and dendritic differentiation, axon 
elimination, and glial cell proliferation, providing a neuronal base for the fetus/neonate to learn 
(Reiss, 1996; reviewed by Georgieff, 2007). At birth, the brain is only 25% of its final volume 
with 70% of cell division complete, but reaches 80% of final adult weight by the end of the 
“growth spurt”, in the first year of life (Crawford, 1993; Helland et al., 2003).  
1.3.2 Importance of n-3 and n-6 LCPUFA to the developing brain 
N-3 and n-6 LCPUFAs are important components of tissue lipids. Specifically, their 
structural and functional roles are centered in cell membranes where they are integrated into 
phospholipids (Neuringer et al., 1988; reviewed by Kidd, 2007). While ARA, the primary n-6 
LCPUFA, is present in all biological membranes and comprises 5 – 15% of total fatty acids in 
most tissue phospholipids, DHA, the primary n-3 LCPUFA, is highly concentrated in the 
cerebral cortex and retina (Neuringer et al., 1988). Specifically, DHA is enriched in brain gray 
matter as 10 – 16% of total fatty acids and rod and cone outer segment membranes of the retina 
as 35% of total fatty acids (Sastry, 1985; Guisto et al., 2002; reviewed by Wall et al., 2010). 
Overall, approximately 64% of total lipids in the adult brain are LCPUFAs, virtually all of which 
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are structural and unavailable for energy metabolism (Yehuda et al., 1999). These concentrations 
are consistent across mammalian species, despite disparities in dietary intake, suggesting a 
functional role for ARA and DHA in brain tissue (Crawford et al., 1976).  
At term, the infant brain contains relatively more ARA than DHA, but higher DHA 
accretion persists after birth, resulting in DHA as the predominant LCPUFA in the adult brain 
(Farquharson et al., 1992; Martinez, 1992a; Martinez and Mougan, 1998). Accrual of brain ARA 
and DHA increases 3 – 5 times in the last trimester of pregnancy and continues throughout the 
first 18 months of life, though at a slower rate (Neuringer et al., 1988; reviewed by Colombo, 
2011). The rate at which ARA and DHA are incorporated into the brain during early postnatal 
life is 10 times faster than that of their respective precursors, LA and α-LA (Greiner et al., 1997).  
 The developing brain is sensitive to environmental insults, including nutritional deficits. 
Critical periods of vulnerability occur during the perinatal period, when development of 
underlying neuronal circuitry is more susceptible to perturbations than at any other time (Anand 
and Scalzo, 2000). This critical period corresponds to peak rates of brain growth, myelination, 
and accelerated production of synaptic sites (Rakic, 1998).  
Neuronal cell growth and development are dependent on all nutrients, but are especially 
responsive to LCPUFA. Deficiency of these fatty acids during fetal or neonatal life can result in 
detrimental global- and/or circuit-specific effects, based on timing and degree of the deficit 
(reviewed by Georgieff, 2007). The developing brain is plastic and amenable to repair after 
nutrient repletion. However, vulnerability to insult likely outweighs plasticity as early nutritional 
deficits manifest themselves as brain dysfunction during the deficit with continued dysfunction 
after nutrient repletion (reviewed by Georgieff, 2007). 
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ARA is involved in cell signaling pathways and is a precursor to eicosanoids that 
participate in cellular processes; however, the specific functional role(s) of DHA in the brain are 
not as well defined (Bhattacharya et al., 1989). Several roles for DHA in the excitable 
membranes of the nervous system and retina have been proposed: i) high polyunsaturation of 
DHA influences biophysical properties of membranes, such as molecule shape and fluidity; ii) 
DHA modulates aspects of lipid-protein interactions, such as activities of membrane-bound 
enzymes and receptors; and iii) DHA is a precursor for functionally important eicosanoid 
products (Spector and Yorek, 1985; Neuringer et al., 1988). 
1.3.3 Accretion of fetal ARA and DHA, as related to the developing brain 
The fetus accumulates approximately 212 mg/kg ARA and 45 mg/kg DHA per day 
during the last trimester of pregnancy (Lapillone and Jensen, 2009). The primary determinant of 
availability and delivery of a fatty acid to the fetus is the concentration of that fatty acid in 
maternal circulation, which is closely related to maternal intake (Haggarty et al., 1999).  
Tracer studies indicate rate of fetal ARA synthesis is significantly greater than that of 
DHA, suggesting the fetus has a greater ability to regulate ARA supply by de novo synthesis 
from LA or placental re-uptake. Thus, it has been proposed that exogenously derived DHA may 
be more critical than ARA during fetal life (reviewed by Haggarty, 2004). However, Western 
diets are notoriously low in DHA. Therefore, maternal stores may be insufficient to meet fetal 
DHA demands for optimal development. This hypothesis remains untested, however, as data on 
DHA accumulation in human placenta and other pregnancy-related tissues, or losses in turnover, 




Unique biological processes, termed “progressive biomagnification” direct DHA and 
ARA from maternal liver to the placenta, fetal liver and, ultimately, fetal brain. Clinically, 
biomagnification is evident by comparing circulating maternal fatty acid concentrations with 
cord venous concentrations, which represent fetal circulation, at delivery. ARA and DHA are 
enriched in cord erythrocyte phospholipids relative to maternal erythrocyte phospholipids (30 – 
35% increase, by weight), although precursor fatty acids are greater in maternal circulation 
(Wijendran et al., 2000). These processes ensure LCPUFAs are selectively supplied to the fetus 
and subsequently incorporated into the brain (Neuringer et al., 1988). 
1.3.4 Accretion of postnatal ARA and DHA, as related to the developing brain 
The importance of DHA extends to postnatal life, as the brain is still developing. 
Postnatally, accretion of infant ARA and DHA depend on the diet and, to a limited extent, 
endogenous synthesis (Birch et al., 2007).  
Brenna et al. (2007) estimated that, worldwide, human breast milk contains an average of 
0.32% of fatty acids as DHA. In United States populations, however, human breast milk contains 
an average of 0.15 – 0.19% of fatty acids as DHA (Auestad et al., 2001; Jensen et al., 2000; 
Yuhas et al., 2006). Breast milk fatty acids are derived from maternal body stores and diet 
(Demmelmair et al., 1998). Thus, lower n-3 LCPUFAs in breast milk from United States 
populations reflects consumption of the n-6 PUFA-saturated Western Diet.  
Infants fed formula without DHA have lower brain cortex and erythrocyte DHA 
concentrations than breast-fed infants (Makrides et al., 1994). Similarly, unsupplemented 
formula-fed infants have 11 – 40% lower DHA concentrations in brain gray matter than breast-
fed infants (Farquharson et al., 1992; Jamieson et al., 1999). It is important to note these studies 
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were conducted when commercial infant formulas were not fortified with DHA. Thus, these 
observations illustrate that diet can modify DHA composition of the developing human brain.  
As in fetal life, neonatal synthesis of ARA is significantly greater than that of DHA 
(reviewed by Haggarty, 2002). It has been estimated that DHA requirements are not addressed 
by endogenous synthesis in a significant capacity until 16 weeks after term delivery (Uauy et al., 
2000; Carnielli et al., 2007); this time frame would presumably be greater in a preterm infant. 
After birth, acylated DHA in liver and adipose tissue decrease, mirroring an increase of acylated 
DHA in the brain and retina. This finding suggests that the liver and adipose tissues sequester 
DHA in utero to provide a reservoir during early neonatal life (Martinez, 1992b). 
1.3.5 Deficits and benefits of ARA and DHA in preterm infants 
Preterm infants (<37 gestational weeks) are more vulnerable to DHA deficits than term 
infants as they are not exposed to maternal fatty acid stores for the entirety of the third trimester 
and have an extremely limited ability to synthesize DHA from the precursor fatty acid (reviewed 
by Kidd, 2007). Consequences for these deficits include increased risk for compromised 
cognitive ability and behavioral impairment at school age. Degree of risk is directly proportional 
to level of immaturity at birth (Bhutta et al., 2002).  
Preterm (and term) infants fed formulas enriched with DHA have similar erythrocyte 
DHA concentrations as breast-fed infants (Carlson et al., 1987; Makrides et al., 1994). By 
improving DHA status, visual acuity of term and preterm infants improves, with greater 






1.3.6 Maternal DHA supplementation and term infant outcome  
 Studies evaluating the effect of maternal DHA supplementation on infant outcome, as 
presented in Table 1.3, largely support the “fetal origins hypothesis”, the theory that fetal 
exposure to in utero conditions, including nutrition deficits or abundances, is related to risk for 
chronic diseases in later life (Barker, 1992). The “fetal origins hypothesis” is discussed in greater 
depth in Section 1.4. 
Table 1.3 Effects of DHA supplementation during pregnancy on infant outcome 
Observations vs placebo Dose per day Duration of suppl. Reference 
Cognitive/central nervous system maturity1 
Improved performance on 
Mental Processing 
Composite of KABC at 4 y 
0.118 g DHA GW 18 – 3 mo Helland et al., 2003 
Less distractibility at 12 – 
24 mo 
0.135 g DHA GW 24/28 - delivery Colombo et al., 2004 
Improved problem solving 
at 9 mo 
0.214 g DHA GW 24 – delivery Judge et al., 2007a 
Improved hand eye 
coordination on GMDS at 
2.5 y 
2.200 g DHA GW 20 – delivery Dunstan et al., 2008 
Improved sleep organization 
at 1 and 2 d 
0.214 g DHA GW 24 – delivery Judge et al., 2012 
Visual acuity 
Improved visual acuity at 4 
mo 
0.214 g DHA  GW 24 – delivery Judge et al., 2007b 
Improved visual acuity at 2 
mo 
0.400 g DHA GW 16 – delivery Innis and Friesen, 2008 
Body composition 
Decreased BMI at 21 mo 0.200 g DHA  GW 21 – 3 mo Bergmann et al., 2007 
Decreased ponderal index at 
birth 
0.214 g DHA  GW 21 – delivery Courville et al., 2011 
1DHA: docosahexaenoic acid; GW: gestational week; KABC: Kaufman Assessment Battery for Children; 
GMDS: Griffiths Mental Developmental Scales 
 
Supplemental DHA during pregnancy improves infant central nervous system maturity, 
assessed as cognitive performance, as early as 9 months and out to 4 years of age (Helland et al., 
2003; Colombo et al., 2004; Dunstan et al., 2006; Judge et al., 2007a). These observations have 
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been reported with a range of DHA intakes (120 – 220 mg per day), at different intervention 
times (16 – 24 weeks of gestation throughout term delivery), and with various validated, age-
appropriate assessment tools (Kaufman Assessment Battery for Children, Griffiths Mental 
Developmental Scales, problem solving tasks). Using aggregation analysis, Cohen et al. (2005) 
estimated that for every increase in maternal intake of 100 mg DHA per day during pregnancy, 
child IQ increases by 0.13 points, with an average maximum benefit of 1.3 IQ points.  
Infants whose mothers received 210 – 400 mg DHA per day during pregnancy have 
improved visual acuity at 2- and 4-months of age as compared to infants born to women 
receiving no supplemental DHA (Judge et al., 2007b; Innis and Friesen, 2008). A similar dose of 
DHA (approximately 200 mg per day) consumed from 21 weeks of gestation to delivery has also 
been linked to improved infant body composition (lower ponderal index and BMI) at delivery 
(Courville et al., 2011) and 21 months of age (Bergmann et al., 2007). 
1.3.7 Postnatal DHA supplementation and term infant outcome 
Significant work, focused on the effects of postnatal DHA supplementation, has been 
conducted and is presented in Table 1.4. Generally, infants receiving supplemental DHA from 
birth to 3 – 4 months of age perform similarly to breast-fed infants on cognitive assessments, 
with both groups performing better than infants not receiving supplemental DHA (Agostoni et 
al., 1995; Birch et al., 2000; Jensen et al., 2005; Jensen et al., 2010; Colombo et al., 2011). 
Cognitive improvements are apparent as early as 4 months of age, extend to 2.5 years of age, and 
have been documented using age-appropriate assessments, including the Brunet-Lézine 





Table 1.4 Effects of postnatal DHA supplementation on infant outcome 
Observations vs placebo Dose Duration of suppl. Reference 
Cognitive/central nervous system maturity1 
Better performance on 
BLPDT for breast-fed and 
formula + DHA at 4 mo 
Breast-fed, formula 
(no DHA), formula 
+ 0.30% FA as DHA 
Birth – 4 mo Agostoni et al., 1995 
Improved performance on 
mental developmental index 
of BSID-II at 18 mo 
Formula (no DHA), 
formula + 0.35% FA 
as DHA 
Birth – 4.25 mo Birch et al., 2000 
Improved performance on 
psychomotor development 
index of BSID at 30 mo 
Breast-feeding 
mothers 
supplemented 0 or 
200 mg DHA/d 
Birth – 4 mo Jensen et al., 2005 
Improved performance on 
the sustained attention 
subscale of the LIPS 
Breast-feeding 
mothers 
supplemented 0 or 
200 mg DHA/d 
Birth – 4 mo Jensen et al., 2010 
Increased sustained attention 
for 0.32 and 0.64% at 4, 6, 
and 9 mo 
0.0, 0.32, 0.64, 
0.92% FA in 
formula as DHA 
Birth – 3 mo Colombo et al., 2011 
Improved information 
processing at 6 y 
Formula (no DHA), 
formula + 0.21% FA 
as DHA  
Birth – 4 mo Willatts et al., 2013 
Visual acuity2 
Higher grating acuity on 
TACP at 2 mo for formula + 
DHA and breast-milk 
Formula (no DHA), 
formula + 0.10% FA 
as DHA, breast-milk 
Birth -  2 mo Carlson et al., 1996 
Better sweep VEP acuity at 
6, 17, and 52 wks for 
formula + DHA 
Formula (no DHA), 
formula + 0.35% FA 
as DHA 
Birth – 17 wks Birch et al., 1998 
Higher VEP acuity at 1 y Formula (no DHA), 
formula + 0.36% FA 
as DHA 
5 – 12 mo Hoffman et al., 2003 
Improved visual acuity at 4 y Formula (no DHA), 
formula + 0.35% FA 
as DHA 








Table 1.4, continued Effects of postnatal DHA supplementation on infant outcome 
Observations vs placebo Dose Duration of suppl. Reference 
Autonomic nervous system3 
Decreased mean- and 
diastolic-BP for formula + 
DHA at 6 y 
Formula (no 
DHA), formula + 
0.20% FA as DHA 
Birth – 4 mo Forsyth et al., 2003 
Decreased systolic BP; 
increased plasma total- and 
LDL-cholesterol for 
formula + DHA at 12 mo 
Formula (no 
DHA), formula + 
DHA (0.37 g 
DHA/d)  
9 – 12 mo Damsgaard et al., 2006 
1DHA: docosahexaenoic acid; FA: fatty acid; BLPDT: Brunet-Lézine Psychomotor Development Test; BSID: 
Bayley Scales of Infant Development; LIPS: Leiter International Performance Scale 
2TACP: Teller Acuity Card Procedure; VEP: visual evoked potential 
3Studies assessing heart rate and heart rate variability, autonomic indices, are covered in Section 1.4 and not 
included here; BP: blood pressure 
 
Although the amount of DHA consumed in the aforementioned studies varied and, in 
some cases, was impossible to calculate due to non-reporting of volume consumed, the 
concentration commonly supplemented (0.30% of total fatty acids) is similar to the worldwide 
average DHA concentration in human breast milk (0.32% of total fatty acids; Brenna et al., 
2007). Cohen et al. (2005) estimated that for every 1% increase in breast milk or formula DHA 
phospholipids, child IQ increases by 4.6 points. This impact on child IQ was greater than that 
when the same amount of DHA was consumed by the mother during pregnancy. Complementing 
observations from maternal DHA supplementation during pregnancy, it has been reported that 
infants receiving DHA as formula or breast-milk have better visual acuity than those fed standard 
formula not enriched with DHA (Carlson et al., 1996; Birch et al., 1998). These group 
differences manifested themselves by 6 weeks and remained present at 52 weeks of age. 
Postnatal DHA plays a role in autonomic development. Forsyth et al. (2003) observed a 
decrease in mean- and diastolic-blood pressure for children at 6 years of age who were 
supplemented with DHA (0.20% of fatty acids) from delivery to 4 months of age. Studies 
25 
 
focused on the relationship between postnatal DHA and infant HR and HRV, autonomic indices, 
are covered in depth in Section 1.4. 
1.3.8 Association between DHA status and term infant outcome  
 Observational studies also point to a relationship between indices of DHA status and 
positive infant outcomes, as presented in Table 1.5. There is a positive association between cord 
plasma phospholipid DHA concentrations and newborn cerebral maturation (Helland et al., 
2001), infant novelty preference at 6 months (Jacobson et al., 2008), performance on mental- and 
psychomotor-development indices at 11 months (Jacobson et al., 2008), and improved motor 
function at 7 years of age (Bakker et al., 2009). Higher DHA concentrations in maternal plasma 
phospholipids at delivery are positively related to more mature sleep patterning, a measure of 
functional central nervous system integrity, at 2 days of age (Cheruku et al., 2002). In terms of  
Table 1.5 Associations between DHA status and infant outcome1 
Associated with increased DHA status Index of DHA status Reference 
Cognitive/central nervous system maturity2 
More mature EEG function at 2 d Cord plasma PL Helland et al., 2001 
More mature sleep patterning at 2 d Maternal plasma PL at 
delivery 
Cheruku et al., 2002 
Greater novelty preference on FTII at 6 mo; 
improved performance on mental- and 
psychomotor-development indices of BSID-II 
at 11 mo 
Cord plasma PL  Jacobson et al., 2008 
Improved motor function at 7 y, assessed by 
MMT 
Cord plasma PL Bakker et al., 2009 
Visual acuity3 
Improved visual acuity at 2- and 12-mo Infant erythrocyte 
phosphatidylethanolamine  
Innis et al., 2001 
More mature retinal development at 1 wk, 
assessed by scotopic ERG 
Cord erythrocyte  Malcolm et al., 2003 
Improved visual acuity at 6 mo Cord plasma PL Jacobson et al., 2008 
1DHA: docosahexaenoic acid 
2PL: phospholipid; EEG: electroencephalography; FTII: Fagan Test of Infant Intelligence; BSID: Bayley Scales of 




visual acuity and retinal development, improved measures are positively associated with DHA in 
cord and infant blood and are clinically apparent from 1 week to 12 months of age (Innis et al., 
2001; Malcolm et al., 2003; Jacobson et al., 2008).  
1.3.9 Recommended ARA and DHA intake during pregnancy and infancy 
A committee tasked with determining optimal fat intake during pregnancy and lactation 
concluded that the only fatty acid requiring alteration, in terms of intake, in the diet of pregnant 
women was DHA (Koletzko et al., 2007). The committee recommended pregnant women 
consume 200 mg DHA per day, but recognized intakes up to 1000 mg DHA per day are without 
adverse outcome. Taken together with amounts supplemented and corresponding observations 
cited in the studies discussed above (Tables 1.3, 1.4, and 1.5), 200 mg DHA per day is 
conservative and will likely fulfill absolute maternal and fetal/infant requirements, but not result 
in “optimal” outcome (ie., infant IQ would continue to increase with > 200 mg DHA; Janssen 
and Kiliaan, 2014). 
Recommendations for preterm and term infants differ, as preterm infants are not exposed 
to maternal fatty acid stores during critical periods of development and, thus, require more 
LCPUFA to accelerate maturation of underdeveloped systems. Recommended DHA and ARA 
concentrations for preterm infants are 0.35 – 1% and 0.40 – 0.80% of total formula fatty acids, 
respectively (Koletzko et al., 2001; Koletzko et al., 2007; Hadders-Algra, 2011; Simmer et al., 
2011; Lapillone et al., 2013). For term infants, it is advised that DHA concentrations are 0.20 – 
0.32% and ARA concentrations are 0.35% of total formula fatty acids. Again, these 
recommendations may be conservative and are estimated to fulfill absolute infant requirement, as 
opposed to “optimize” outcome. However, the recommended DHA concentration clearly exceeds 
that of breast milk from the United States (Auestad et al., 2001; Jensen et al., 2001; Yuhas et al., 
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2006) and is more similar to that of the worldwide average (0.32%) as estimated by Brenna et al 
(2007).  
1.4 Mechanism underlying n-3 LCPUFA effects on heart rate and heart rate variability 
1.4.1 The autonomic nervous system 
The autonomic nervous system contains two antagonistic divisions, the sympathetic and 
parasympathetic (vagal) nervous systems (reviewed by Berntson et al., 1997). Autonomic output 
is mediated through preganglionic sympathetic and parasympathetic neurons which innervate the 
heart via the stellate ganglia and vagus nerve, respectively (reviewed by Benarroch, 1993). The 
interaction between these inputs and the sinoatrial (SA) node reflect spontaneous changes in 
autonomic activity which are apparent in HR and HRV measures (Massin and von Bernuth, 
1997). 
1.4.2 Autonomic innervation of the sinoatrial node 
Autonomic innervation lowers resting HR by 30% of its intrinsic value (reviewed by 
Thomas, 2011). Greater parasympathetic influence further reduces HR, with the opposite 
occurring for greater sympathetic influence (reviewed by Thomas, 2011). Sympathetic 
stimulation, via β-adrenergic receptors and release of norepinephrine, increases SA node 
automaticity and atrioventricular (AV) node conduction, increasing HR (reviewed by Berntson et 
al., 1997; reviewed by Sztajzel, 2004; reviewed by Thomas, 2011). Sympathetic stimulation 
increases the probability pacemaker channels will be open, allowing greater ion flow, increasing 
the steepness of the slope required for depolarization (reviewed by Lilly, 2007; reviewed by 
Thomas, 2011). As a result, nodal cells reach threshold and spontaneously depolarize earlier than 
normal. With greater sympathetic influence, there is also a greater probability that Ca channels 
will be open; this shifts the threshold required for an action potential to more negative voltages, 
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resulting in a lower threshold potential for diastolic depolarization (Trautwein and Kameyama, 
1986; reviewed by Lilly, 2007). 
Parasympathetic stimulation, via muscarinic cholinergic receptors and release of 
acetylcholine (ACh), the primary parasympathetic neurotransmitter, reduces intrinsic firing rate 
of the SA node and slows conduction in the AV node, reducing intrinsic HR (reviewed by 
Berntson et al., 1997; reviewed by Sztajzel, 2004; reviewed by Thomas, 2011). Parasympathetic 
influence decreases the probability pacemaker channels will be open, reducing flow and the 
slope of depolarization. Furthermore, the probability of Ca channels being open decreases in the 
face of parasympathetic stimulation, increasing the action potential threshold to a more positive 
voltage (Noma and Trautwein, 1978). Parasympathetic stimulation also increases the probability 
transmembrane ACh-sensitive K channels will be open at rest, resulting in a more negative 
maximum diastolic potential (Sakmann et al., 1983; reviewed by Lilly, 2007).  
1.4.3 Autonomic influence on circulating cytokines and catecholamines 
Innervation of the SA node is a direct mechanism by which the autonomic nervous 
system controls HR and HRV. A separate, indirect autonomic mechanism also exists. By 
modulating circulating inflammatory factors (i.e., cytokines) and catecholamines, the autonomic 
nervous system indirectly affects HR and HRV. 
Electrical or mechanical stimulation of the vagus nerve and the resulting increase in 
parasympathetic tone reduces cytokine production (Borovikova et al., 2000). Further, peripheral 
release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18), but not anti-inflammatory 
cytokines (IL-10), is attenuated by ACh (Borovikova et al., 2000). The interaction between ACh 
and the α-7 nicotinic ACh receptor subunit, expressed on cytokine-producing cells, is the 
molecular basis for this anti-inflammatory circuit (Wang et al., 2002).  
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This relationship has been observed in vivo; CRP levels are inversely related to surrogate 
measures of vagus nerve activity in healthy individuals (Sloan et al., 2007) and individuals with 
coronary heart disease (Frasure-Smith et al., 2009). Further, IL-6 levels in individuals with 
coronary heart disease are inversely related to HRV measures before covariate adjustment 
(Frasure-Smith et al., 2009). 
The sympathetic nervous system also indirectly modulates HR by increased 
catecholamine release and pro-inflammatory cytokine production (reviewed by Lilly, 2007; 
Nance and Sanders, 2007). Stimulation of β-adrenoreceptor (a target of sympathetic-derived 
catecholamines) increases gene expression and protein production of pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6) in myocardial cells (Murray et al., 2000) and β-blockade reduces plasma 
IL-6 in patients with congestive heart failure (Mayer et al., 2005). Further, stress-induced 
activation of NFκB, a mediator of TNF-α responses (Beg and Baltimore, 1996), is dependent on 
the primary sympathetic neurotransmitter, norepinephrine, and this activation can be abrogated 
by α1-adrenoreceptor blockade (Bierhaus et al., 2003).  
1.4.4 Autonomic maturation and age-dependence of heart rate and variability 
 Autonomic control is affected by age, especially during the perinatal period. These age-
related autonomic changes are characterized by differences in the sympathetic:parasympathetic 
(sympathovagal) balance (Chatow et al., 1995; Massin and von Bernuth, 1997).  
Heart rate decreases with increasing age (Finley and Nugent, 1995; Umetani et al., 1998); 
however, HRV changes through life are not linear or as clear. The sympathetic nervous system 
matures earlier than the parasympathetic nervous system and is predominant in early fetal life 
(Assali et al., 1978; Siimes et al., 1990; Chatow et al., 1995). At approximately 35 – 36 weeks of 
gestation, there is a pronounced increase in parasympathetic tone (Ramet et al., 1991). This 
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becomes clinically apparent during the third trimester. Fetal HRV differences among groups can 
be observed as early as 32 – 34 weeks of gestation (Groome et al.,1999; Gustafson et al., 2013) 
and remain age-dependent throughout the lifespan (Finley and Nugent, 1995).  
Infants exhibit the most profound changes in HR and HRV of any life stage (Finley and 
Nugent, 1995), and this is at least partially attributable to the significant degree of autonomic 
maturation that occurs during this time (Massin and von Bernuth, 1997). Individual differences 
in HRV originate in utero and persist postnatally (DiPietro et al., 2007; van Leeuwen et al., 
2013), suggesting HRV is established during development and related to postnatal values. 
 In general, low HR and high HRV are hallmarks of health (Stein et al., 2005), although 
there is a threshold beyond which greater decreases in HR and/or increases in HRV would 
indicate abnormal functioning (Simopoulos, 1991). Heart rate and HRV are easily assessed in 
populations across the age continuum (Massin and von Bernuth, 1997), and these measures may 
indirectly reflect cardiac health and cardiac-autonomic integration. 
1.4.5 Relationship between n-3 LCPUFA, heart rate, and variability in different populations 
Dietary fats are ubiquitous components of cell membranes, including those of the 
cardiovascular system (reviewed by Simopoulos, 1991). Fatty acid composition of cell 
membranes reflects that of the diet (reviewed by Simopoulos, 1991), implying that dietary 
interventions may affect cardiac health, reflected as alterations in HR and HRV. Further, HR and 
HRV are modulated by the autonomic nervous system, which may also be impacted by dietary 
fat intake.  
The LCPUFA of the n-3 family, EPA and DHA, have been studied extensively with 
regard to human health. There is interest in exploring if these fatty acids affect HR and HRV. 
Similar to the age-dependence of HR and HRV (Finley and Nugent, 1995), which is largely 
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dictated by autonomic control, the effect of n-3 LCPUFA supplementation depends on the 
population. 
1.4.6 Effect of n-3 LCPUFA on heart rate and variability: fetuses and infants 
 The perinatal period is a sensitive time during which nutrition may have programming 
effects on later infant health and outcome (Barker et al., 1993; reviewed by Das, 2004). In 
fetuses and infants, HRV is considered a developmental expression of maturation, thought to be 
linked to parasympathetic activity and the integrity of the developing autonomic nervous system 
(Richards and Cameron, 1989; Massin and von Bernuth, 1997; Longin et al., 2005; Gustafson et 
al., 2013). The autonomic nervous system significantly matures during perinatal life (Massin and 
von Bernuth, 1997); therefore, provision or deficits of nutrients during this time may exert long-
term effects (reviewed by Christensen, 2011).  
Colombo et al. (2011) administered 3 levels of DHA (0.32, 0.64, and 0.92% of fatty acids 
as DHA) to term infants from birth to 12 months of age and measured HR at 4, 6, and 9 months. 
Groups receiving supplemental DHA had lower HR than the control group receiving no DHA; 
this effect was not dose-dependent. Similarly, term infants who were breast-fed, fed DHA-
enriched milk formula, or fed DHA-enriched soy formula had lower HR and higher HRV than 
infants fed a DHA-deficient soy formula (Pivik et al., 2009). These effects were documented 
from 4 to 12 months of age. In another study (Lauritzen et al., 2008), male infants receiving 924 
mg fish oil, a source of n-3 LCPUFA, per day from 9 to 12 months of age had lower HR than 
those receiving no supplemental fish oil; no effect was observed in female infants. There was a 
positive association between the changes in HR and erythrocyte n-3 PUFA content, regardless of 
gender (Lauritzen et al., 2008) 
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Gustafson et al. (2013) explored if maternal supplementation of n-3 LCPUFA during 
pregnancy affected the developing fetus. Pregnant women were supplemented with 600 mg DHA 
per day or a placebo from gestational week 14.4 to term delivery. Fetal HR and HRV were 
assessed at 24, 32, and 36 weeks of gestation with magnetocardiography. There was a trend for 
lower fetal HR and higher indices of HRV, assessed as time-domain metrics.  
1.4.7 Effect of n-3 LCPUFA on heart rate and variability: healthy adults 
 In healthy adults, HR and HRV are prognostic markers for later cardiovascular morbidity 
and mortality (Tibblin et al., 1974; Mølgaard et al., 1991; Gillman et al., 1993; Dekker et al., 
1997; Hjalmarson, 1998; Curtis and O’Keefe, Jr., 2002). Low HRV indicates the autonomic 
nervous system has been strained by chronic excessive sympathetic tone and/or diminishment of 
parasympathetic tone (Curtis and O’Keefe, Jr., 2002). Interventions that shift autonomic balance 
to favor parasympathetic dominance and minimize sympathetic regulation improve disease 
prognosis (Curtis and O’Keefe, Jr., 2002). 
 In a meta-analysis of intervention trials including healthy adult populations (n = 16) and 
populations of adults with at least 1 chronic condition (n = 22), n-3 LCPUFA intake significantly 
reduced HR by 1.6 beats per minute (bpm) versus a placebo, with no effect of intake amount 
(Mozaffarian et al., 2005). When examining only those trials conducted in healthy adults, there 
was still a reduction in HR with n-3 LCPUFA intake, albeit a smaller effect, 1.4 bpm 
(Mozaffarian et al., 2005). Although the meta-analysis evidenced an overall HR-lowering effect 
in accordance with n-3 LCPUFA intervention in healthy adults (Mills et al., 1989; Vandogen et 
al., 1993; Conquer and Holub, 1998; Christensen et al., 1999; Dyerberg et al., 2004; Stark and 
Holub, 2004; Mozaffarian et al., 2005; Ninio et al., 2008), a HR-raising effect (Mills et al., 1990; 
33 
 
Geelen et al., 2003; Monahan et al., 2004), and mixed effects (Desylpere, 1992; Grimsgaard et 
al., 1998) have also been reported. 
 The relationship between n-3 LCPUFA and HRV in healthy populations is inconsistent. 
A cross-sectional study in Inuit adults, a population known for significant fish and marine 
mammal consumption, indicates a positive association between n-3 LCPUFA levels in 
erythrocyte membranes and HRV indices for females, but not males (Valera et al., 2011). In 
contrast, a positive association between blood n-3 LCPUFA levels and HRV has been observed 
in males (Christensen et al., 1999; Brouwer et al., 2002; Dallongeville et al., 2003). 
In intervention trials, n-3 LCPUFA supplementation has been found to increase (Ninio et 
al., 2008) and decrease (Geelen et al., 2003; Dyerberg et al., 2004) HRV in healthy adults, while 
others have found no effect of intervention (Christensen et al., 1999). Using spectral analysis to 
assess HRV, Sjoberg et al. (2010) observed a shift in the low to high frequency ratio with 
increasing doses of fish oil, indicating a shift toward parasympathetic regulation. 
Inconsistent findings could be due to heterogeneous populations and differences in 
sample design (intervention time, duration, and/or dosage), but could also be attributed to the 
analysis and interpretation of HR and HRV. Heart rate and HRV data can be derived from 
recordings ranging from 5 minutes to 24 hours. Further, HRV can be analyzed using time- or 
frequency (spectral)-domain metrics. Thus, it is difficult to conclude with certainty if, and to 
what extent, n-3 LCPUFA intake affects HR and HRV in healthy adults. 
1.4.8 Effect of n-3 LCPUFA on heart rate and variability: cardiovascular diseases 
 The extent to which n-3 LCPUFA intake decreases HR is more dramatic in diseased 
populations than healthy adults. N-3 LCPUFA intervention has a HR-lowering effect of 2.7 bpm 
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in adults with coronary artery disease versus a reduction of 1.3 bpm in healthy adults 
(Mozaffarian et al., 2005). 
 Individuals at risk for a subsequent cardiac event commonly have blunted HRV (Zipes 
and Wellens, 1998). There is a positive association between n-3 LCPUFA consumption and 
HRV in adults who have previously suffered a myocardial infarction and have left ventricular 
dysfunction (Christensen et al., 1997). A similar association has been observed in individuals 
who are suspected to have ischemic heart disease (Christensen et al., 2001). In comparison with a 
placebo, n-3 LCPUFA increase indices of HRV in adults with cardiovascular disease 
(Christensen et al., 1996; O’Keefe, Jr. et al., 2006; Nodari et al., 2009; Carney et al., 2010). In 
contrast, Hammad et al. (2006) noted a HRV-lowering effect of n-3 LCPUFA in adults with 
coronary artery disease. 
1.4.9 Potential mechanisms by which n-3 LCPUFA modulate heart rate and variability 
In summary, n-3 LCPUFA intake is associated with decreased HR and increased HRV 
indices across the lifespan and for different health conditions (Christensen et al., 1999; Holguin 
et al., 2005; Mozaffarian et al., 2005; Mozaffarian et al., 2008; Sjoberg et al., 2010), although 
contradictory findings have also been reported for HR (Mills et al., 1990; Desylpere, 1992; 
Grimsgaard et al., 1998; Geelen et al., 2003; Monahan et al., 2004) and HRV (Christensen et al., 
1999; Geelen et al., 2003; Dyerberg et al., 2004). The mechanism behind this association 
remains a source of controversy. Common hypotheses are that n-3 LCPUFA intake affect HR 
and HRV by: i) autonomic modulation (Hibbeln et al., 2006; Gustafson et al., 2008), ii) changes 
in cardiac electrophysiology (Harris et al., 2006; Mozaffarian et al., 2006; Kang, 2012), and/or 
iii) autonomic modulation of circulating cytokines and catecholamines (Berntson et al., 1997). 
These potential mechanisms, along with existing evidence for each, are presented here. 
35 
 
1.4.10 n-3 LCPUFA affect heart rate and variability by autonomic modulation: evidence  
The mechanism linking n-3 LCPUFA intake and direct autonomic effects on HR and 
HRV is possibly two-fold and rooted in ACh, the primary vagal neurotransmitter. Firstly, in 
animal models, dietary n-3 LCPUFA modulates hippocampal and cerebral ACh levels (Minami 
et al., 1997; Favreliere et al., 2003; Aïd et al., 2005) without affecting ACh-esterase activity (Aïd 
et al., 2005; Shahdat et al., 2004), leading to an overall increase in ACh. Secondly, α-LA, the 
precursor of EPA and DHA, induces a long-term enhancement of ACh receptors (Nishizaki et 
al., 1997). This is mediated by activation followed by phosphorylation of the receptor’s protein 
kinase (Nishizaki et al., 1997) and would presumably occur with the longer chain n-3 derivatives 
of α-LA, as well, although this interaction has not been explored, to the authors’ knowledge.  
It is noteworthy that, in the study by Nishizaki et al. (1997) the n-6 PUFA precursor, LA, 
had the same effect on ACh receptors as α-LA. Further, these findings were reported using 
nicotinic receptors in Xenopus oocytes, which may not be consistent with neuronal nicotinic ACh 
receptors in vivo. Nevertheless, an increase in brain ACh levels with n-3 LCPUFA intake has 
been reported in several animal models (Minami et al., 1997; Favreliere et al., 2003; Aïd et al., 
2005), although it remains unclear if this is at least partially due to an enhancement in ACh 
receptors. An increase in brain ACh increases parasympathetic tone with corresponding 
decreases and increases in HR and HRV, respectively. 
1.4.11 n-3 LCPUFA affect heart rate and variability by modulating cardiac electrophysiology: 
evidence 
 
Another mechanism by which n-3 LCPUFA potentially alter HR is by directly 
influencing myocardial voltage-gated ion channels. Harris et al. (2006) investigated the effects of 
n-3 LCPUFA on HR in heart transplant recipients, the hearts of whom were functionally 
denervated and, thus, void of direct autonomic control. The reduction in HR after 4 – 6 months 
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of n-3 LCPUFA supplementation was similar for denervated and innervated individuals. The 
authors asserted the observed effects involve electrophysiological alterations to the myocardium 
and suggested the autonomic nervous system is not essential to lower HR. 
 Using cell culture, it was demonstrated that n-3 LCPUFA directly affect cardiac cell 
membrane electrical excitability (Kang and Leaf, 1994; Kang et al., 1995; Xiao et al., 1995; 
Kang and Leaf, 1996; Leaf, 2001). These findings, along with those of Harris et al. (2006) 
prompted the hypothesis that n-3 LCPUFAs lower HR by altering intrinsic HR at the level of the 
myocardium. 
 Using isolated neonatal rat cardiac myocytes, which beat independently of neural or 
hormonal inputs, Kang and Leaf (1994) observed that treatment with n-3 LCPUFA reduced 
myocyte contraction rate without affecting amplitude. To further demonstrate that n-3 LCPUFA 
can suppress the automaticity of cardiac contraction, the researchers investigated the response of 
cardiac myocytes to electrical pacing by pairing a series of stimulating impulses with addition of 
n-3 LCPUFA to cell media (Kang and Leaf, 1996). Exposure of cardiac myocytes to n-3 
LCPUFA slowed, then maintained a reduced contraction rate, which returned to its previous 
value after treatment removal.  
Using a patch-clamp technique in cardiac myocytes treated with n-3 LCPUFA, Kang et 
al. (1995) induced an action potential and measured the required strength of the current. In the 
presence of n-3 LCPUFA, a greater depolarizing current was necessary to induce an action 
potential as the result of a threshold increase and more negative resting membrane potential. 
Finally, the effects of n-3 LCPUFA on single ion channel activity was observed. Using 
the neonatal rat cardiac myocyte model, addition of n-3 LCPUFA to cell media inhibited Na 
currents (Xiao et al., 1995), which is in line with similar work demonstrating an effect on Na and 
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Ca channels (Leaf, 2001). The depolarizing stimulus required to induce an action potential was 
increased by 40 – 50% and the refractory period was prolonged three-fold (Leaf, 2001). 
Thus, by modulating conductance of the myocardial Na and Ca channels, n-3 LCPUFA 
increase the depolarizing current required to elicit an action potential and prolong the refractory 
period, resulting in an overall reduction in HR. Together, these studies provide a basis for the 
hypothesis that the mechanism by which n-3 LCPUFA reduce HR is electrophysiological. There 
is no evidence exploring this mechanism with specificity to HRV, to the authors’ knowledge. 
1.4.12 n-3 LCPUFA affect heart rate and variability by modulating circulating factors: evidence 
Section 1.4.3 documents evidence of autonomic-directed alterations in circulating 
cytokines and catecholamines. As n-3 LCPUFA shift sympathovagal balance to favor increased 
parasympathetic tone (Pluess et al., 2007; Sjoberg et al., 2010) and are documented in their 
ability to alter circulating cytokines (Meydani et al., 1991; Gallai et al., 1993; Caughey et al., 
1996), these fatty acids can presumably indirectly affect HR and HRV via modulation of 
circulating factors.  
In individuals exposed to an endotoxin challenge, those receiving an intravenous fish oil 
emulsion before exposure had enhanced parasympathetic activity (assessed with frequency-
domain HRV), suppressed plasma norepinephrine, and reduced circulating TNF-α versus the 
untreated group (Pluess et al., 2007). Supplementation with n-3 LCPUFA shifts plasma 
catecholamine concentrations to a more favorable epinephrine to norepinephrine ratio (Pluess et 
al., 2007; Hamazaki et al., 2005), indicating a suppression of sympathetic tone.  
N-3 LCPUFA directly affect cytokine production and release by various methods, 
including competition with n-6 fatty acids for shared enzymatic pathways and altered expression 
of inflammatory genes via transcription factors (reviewed by Calder, 2002; reviewed by Calder, 
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2006), covered in full in Section 1.1. This suggests n-3 LCPUFA can also affect circulating 
inflammatory factors independent of autonomic modulation which, in turn, may affect HR and 
HRV. 
1.4.13 Hypothesis 
 The mechanism by which n-3 LCPUFA affect HR and HRV is not fully elucidated. 
However, there are three potential mechanisms, presented above. These are not the only 
mechanisms proposed, however, they are commonly cited and have recently received attention.  
While n-3 LCPUFA can directly influence the automaticity of cardiac myocytes, when 
PUFA are consumed, they bind albumin and other proteins and are unlikely to directly affect the 
myocardium unless they are incorporated into the phospholipid fraction of the myocardial cell 
membrane pool (reviewed by Das, 2000). Thus, those studies utilizing cardiac myocytes (Kang 
and Leaf, 1994; Kang et al., 1995; Xiao et al., 1995; Kang and Leaf, 1996; Leaf, 2001) may not 
be applicable for, or have limited relevance to, an in vivo model.  
 Harris et al. (2006) noted a reduction in HR in cardiac transplant patients given capsules 
containing n-3 LCPUFA for 4 – 6 months and attributed their findings to modification of 
myocardial electrophysiological properties by n-3 LCPUFA. However, in denervated 
individuals, the sympathetic and parasympathetic nervous systems can modulate HR and HRV 
indirectly by release of catecholamines and cytokines (Berntson et al., 1997). There is also 
potential for n-3 LCPUFA to affect HR and HRV via cytokine production and release, 
independent of autonomic modulation. These circulating factors would impart their effects 
despite cardiac denervation (Lilly, 2007).  
Harris et al. (2006) noted significant effects on the QRS complex but not the QTc-
interval in cardiac transplant patients after n-3 LCPUFA treatment. The QT interval and QRS 
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complex are both affected by the autonomic nervous system but are also influenced by 
circulating catecholamines (Bexton et al., 1986; Nakagawa et al., 2000), which can be altered by 
n-3 LCPUFA (Hamazaki et al., 2005; Pluess et al., 2007). Similar research indicates that, 
following cardiac denervation, a reduction in HR characteristic of sleep occurs, albeit not as 
great of a reduction as would be observed in normal subjects (Baust and Bohnert, 1969). This 
effect may possibly be attributed to the circadian rhythm of endogenously derived circulating 
catecholamines (Baust and Bohnert, 1969; Barnes et al., 1980; Bexton et al., 1986; Nakagawa et 
al., 2000). Thus, the n-3 LCPUFA effect on the QRS complex reported by Harris et al. (2006) 
may be explained, in part, by alterations in circulating catecholamines as regulated by the 
sympathetic nervous system. 
 In conclusion, there is evidence n-3 LCPUFA affect HR and HRV: 1) directly by 
increasing brain ACh and, thereby, parasympathetic tone, and 2) indirectly by modulating 
circulating factors, dependently and independently of the autonomic branches. Modulation of HR 
and HRV is complicated and could involve other processes, but these mechanisms appear to be 
major contributors to the observed effects, based on evidence presented in the literature. 
Although the hypothesis that n-3 LCPUFA affect HR and HRV via alterations in cardiac 
electrophysiology should not be dismissed, current evidence needs strengthening. Future studies 
assessing the relationship between dietary n-3 LCPUFA, HR, and HRV should also consider 
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CHAPTER 2. MATERNAL FATTY ACID STATUS DURING PREGNANCY IS 
RELATED TO INFANT HEART RATE AND HEART RATE VARIABILITY 
 
2.1 Introduction 
Heart rate (HR) and heart rate variability (HRV) are early life developmental expressions 
of autonomic maturation, reflecting autonomic integrity and cardiac-autonomic integration 
(Massin and von Bernuth, 1997; Richards and Cameron, 1989; Longin et al., 2005; Gustafson et 
al., 2013). Further, individual differences in HRV originate in utero and persist postnatally 
(DiPietro et al., 2007; van Leeuwen et al., 2013), suggesting HRV is established during fetal life 
and related to postnatal measures. 
Consumption of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), n-3 long 
chain polyunsaturated fatty acids (LCPUFAs), impacts HRV across the lifespan and in healthy 
and diseased states, as reviewed by Christensen (2011). There is a positive association between 
cellular n-3 LCPUFA content and HRV (Brouwer et al., 2002; Christensen et al., 1997; 
Christensen et al., 1999; Christensen et al., 2001). Further, n-3 LCPUFA supplementation 
reduces HR (Ninio et al., 2008; Carney et al., 2010) and increases HRV (Christensen et al., 1996; 
Holguin et al., 2005; Ninio et al., 2008; Carney et al., 2010). Autonomic modulation by n-3 
LCPUFAs is hypothesized to be the mechanism underlying these observations (Hibbeln et al., 
2006; Gustafson et al., 2008). The relationship between n-3 LCPUFAs, HR, and HRV during 
early life mirrors that of adults (Christensen, 2011). 
Male infants receiving 924 mg fish oil, a concentrated source of n-3 LCPUFA, per day 
from 9 to 12 months of age had lower HR than those receiving no supplemental fish oil 
(Lauritzen et al., 2008). Further, there was a positive association between changes in HR and 
erythrocyte n-3 PUFA content for male and females (Lauritzen et al., 2008). Building on these 
observations, Pivik et al. (2009) demonstrated that term infants who were breast-fed, fed DHA-
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enriched milk formula, or fed DHA-enriched soy formula had lower HR and higher HRV from 4 
to 6 months of age than infants fed a DHA-deficient soy formula. Further, term infants 
supplemented with DHA (0.32, 0.64, and 0.92% of fatty acids) from birth to 12 months of age 
had lower HR at 4, 6, and 9 months of age compared to infants who were not supplemented with 
DHA (Colombo et al., 2011). In a randomized clinical trial, Gustafson et al. (2013) demonstrated 
that fetuses of pregnant women supplemented with 600 mg of DHA per day beginning at 14.4 
gestational weeks trended towards lower HR and had higher HRV at 24, 32, and 36 gestational 
weeks than fetuses of mothers receiving a placebo.  
The autonomic nervous system, especially the parasympathetic (vagal) nervous system, 
matures significantly during the third trimester (Porges and Furman, 2011). Therefore, provision 
or deficits of nutrients during this vulnerable developmental period may exert long-term 
programming effects (Christensen, 2011). The fetus inefficiently converts DHA from precursors 
(Carnielli et al., 1996; Salem et al., 1996), thus, the primary determinant of fetal availability and 
delivery of n-3 LCPUFAs is the concentration in maternal circulation (Haggarty, 1999). 
The studies outlined above examine the effects of maternal n-3 LCPUFA 
supplementation on fetal HR and HRV (Gustafson et al., 2013) and of postnatal n-3 LCPUFA 
supplementation on infant HR and HRV (Lauritzen et al., 2008; Pivik et al., 2009; Colombo et 
al., 2011). However, to the best of our knowledge, the relationship between maternal fatty acid 
status during pregnancy and infant HR and HRV have not previously been explored. 
 The aim of the current trial was to assess the relationship between maternal fatty acid 
status during pregnancy and infant HR and HRV during the first 6 months of life. Fatty acids of 
specific interest were LCPUFA of the n-3 series, DHA and EPA, and of the n-6 series, 
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arachidonic acid (ARA), along with their respective precursors, as these fatty acid families share 
an enzymatic pathway and are, therefore, metabolically competitive.  
2.2 Methods 
All procedures involving human subjects were approved by the Louisiana State 
University AgCenter, Woman’s Hospital, and Pennington Biomedical Research Center 
Institutional Review Boards.  
2.2.1 Participants 
 Participants enrolled in a larger study (LA Moms and Babies Study [LAMBS] for 
Nutrition and Growth) were invited to enroll in the current study. For the larger study, women 
were recruited from an obstetrics and gynecology clinic, Associates in Women’s Health, 
Woman’s Hospital in Baton Rouge, LA. Women were invited to participate in the study if they: 
were 18 – 35 years of age, had a singleton pregnancy, were between 17 and 20 gestational 
weeks, and had a pre-pregnancy body mass index of 25.0 – 29.9. Exclusion criteria included: 
history or current diagnosis of high blood pressure, high blood lipids, kidney disease, liver 
disease, polycystic ovarian syndrome, HIV, or diabetes mellitus (type 1, type 2, or gestational); a 
first degree relative diagnosed with diabetes mellitus (type 1 or type 2); uncontrolled thyroid 
disorder; smoking in the past 6 months; parity > 5; pre-term birth (≤ 37 gestational weeks); 
positive test for group B streptococcus, syphilis, or Hepatitis B; and pregnant or lactating within 
the previous 6 months.  
From the LAMBS study, 17 women were approached between 37 gestational weeks and 
1 week after delivery and invited to participate in the current study. Overall, 13 mother-infant 
pairs completed informed consent; one mother-infant pair was excluded from analysis due to 
infant diagnosis of congenital heart defects at 6 months of age and one mother-infant pair was 
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excluded from the study for failure to comply with study protocol. Maternal and infant 



















2.2.2 Blood collection and analysis 
Blood collections occurred prior to informed consent for the current study. However, in 
the LAMBS study, informed consent contained an optional clause for collected blood samples to 
Table 2.1 Maternal and infant characteristics, n = 111 
Maternal age (y)  26.7 ± 3.72 
Pregavid BMI (kg/m2) 26.9 ± 1.4 
Race (n)  
     White 4 
     African American 7 
Parity  
     0 4 
     1 5 
     3 2 
Length of gestation (wk) 39.9 ± 1.0 
Birth type (n)  
     Vaginal 9 
     Cesarean 2 
Infant birth weight (kg) 3.4 ± 0.4 
Infant sex (n)  
     Male 2 
     Female 9 
Infant birth length (cm) 7.9 ± 0.3 
Infant head circumference (cm) 5.4 ± 0.3 
1-min Apgar score3 7.8 ± 0.6 
5-min Apgar score3 7.9 ± 0.3 
Breastfed (n)  
     2 wk of age 9 
     4 mo of age 5 
     6 mo of age 3 
1Total number of subjects included in analyses unless otherwise 
noted 
2?̅? ± SD 
3n = 10 
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be used in future, ancillary studies; all women approached for the current study consented to the 
clause. Maternal blood samples were collected at 17-20, 24, 32, and 36 gestational weeks. Blood 
(~10 mL) was sampled from the antecubital vein and collected in EDTA-containing tubes. 
Erythrocytes were separated from plasma by centrifugation (2600 × g at 4°C for 10 min), washed 
in 0.9% saline, portioned, and immediately stored at -80°C until analysis. 
 Erythrocytes were prepared for fatty acid analysis using a direct methylation procedure. 
Prior to methylation, heptadecanoic acid (17:0) was added as an internal standard for calculation 
of relative weight percentages (wt%) of erythrocyte fatty acids. Fatty acid methyl esters (FAME) 
were separated with a Hewlett-Packard 6890 series gas chromatograph (Agilent Technologies, 
Santa Clara, CA) equipped with a flame ionization detector (FID) and an Omegawax® 250 fused 
silica capillary column (30 m × 0.25 mm × 0.25 µm; Sigma-Aldrich, St. Louis, MO). The oven 
temperature was programmed from 180 – 210°C at a rate of 2°C/min with a final hold of 33 min. 
The FID temperature was set at 280°C. Helium was used as the carrier gas and flow was 
maintained at 1.2 mL/min. External standards (FIM-FAME; Matreya, LLC, State College, PA) 
were run with each set of samples. Samples were injected in duplicate. Erythrocyte FAMEs were 
identified by comparison with external standards and expressed as relative wt%. 
2.2.3 Infant heart rate and heart rate variability analysis 
 Continuous ambulatory electrocardiograph monitoring was conducted in infants for a 24 
h period at 2 weeks, 4 months, and 6 months of age with Holter monitors (DigiTrak XT; Philips, 
Amsterdam, NL). Recordings were conducted in the participant’s home. Mothers were 
encouraged to allow infants to engage in normal activities, advised to dress infants in a tight-
fitting onesie to minimize choking hazard, and cautioned against immersing infants in water 
during the recording period. Recordings were analyzed by a certified technician with aid of a 
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diagnostic software program (Philips Zymed Holter 1810 Series, Version 2.9.4) to identify and 
label each QRS complex as normal or abnormal based on morphology and timing. Only QRS 
complexes with normal morphology were used in calculating HR and HRV measures. All 
recordings contained ≥ 23.5 h of analyzable data. 
 Mean HR was calculated as the average of all filtered RR intervals over the 24 h 
recording period. Three time-domain measures reflecting HRV were calculated: 1) SDNN, the 
standard deviation of filtered RR intervals over the 24 h recording period; 2) SDANN, the 
standard deviation of the means of all filtered RR intervals for all 5 min segments of the analysis; 
and 3) ASDNN (also known as SDNN-index), the mean of the standard deviations of all filtered 
RR intervals for all 5 min segments of the analysis.  
Interpretation and application of each time-domain HRV index are outlined in Task 
Force, 1996; Stein and Kleiger, 1999; and Sztajzel, 2004. Each time-domain index is highly 
correlated (r2 ≥ 0.89) to a frequency-domain metric (Bigger Jr. et al., 1992). Time-domain 
analysis quantitates variability while frequency-domain analysis addresses the underlying 
rhythms responsible for that variability (Stein et al., 1994).  
When assessed over a 24 h period, SDNN is an overall metric of HRV which is 
correlated to total power (r2 = 0.96) and reflects all cyclic components contributing to variation, 
including short-term high frequency variations and long-term low frequency components (Task 
Force, 1996; Sztajzel, 2004). Total power, the total variance in the signal, is calculated as the 
summation of high frequency, low frequency, very-low frequency, and ultra-low frequency 
metrics (Stein and Kleiger, 1999). As such, SDNN encompasses parasympathetic- and 
sympathetically-modulated variations in HR. SDANN, which is strongly correlated to the ultra-
low frequency metric (r2 = 0.96), is an estimate of long-term components of HRV and represents 
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variation due to low frequency activities, such as physical activity, postural changes, and 
circadian rhythm (Bigger Jr. et al., 1992; Task Force, 1996; Sztajzel, 2004). ASDNN is 
correlated to very-low frequency (r2 = 0.90) and low frequency metrics (r2 = 0.89) and, thus, 
represents variations related to the thermoregulatory, peripheral vasomotor, and/or renin 
angiotensin systems, as well as oscillatory rhythms of the baroreceptor system (Bigger Jr. et al., 
1992; Stein and Kleiger, 1999).  
2.2.4 Statistical analyses and calculations 
 Statistical analyses were performed using SAS, by SAS Institute, Inc., version 9.4 (Cary, 
NC). For all measures, level of significance was set at ≤ 0.05 and trends were ≤ 0.10. Repeated 
measures of HR and HRV at 2 weeks, 4 months, and 6 months of infant age were analyzed using 
a randomized block design with factors infant (blocking factor) and time. Individual one-tailed t-
tests were used to describe changes in HR and HRV between timepoints (2 weeks to 4 months; 4 
months to 6 months; 2 weeks to 6 months).  
Simple linear and multiple backward stepwise regression analyses were performed to 
explore associations between maternal erythrocyte fatty acids (independent or predictor 
variables) during pregnancy and infant HR and HRV (dependent variables). In most cases, it was 
impossible to assess HR/HRV at exactly 2 weeks, 4 months, or 6 months of infant age. This, 
combined with HR and HRV changes that are a natural reflection of advancing age during the 
first 6 months of life (Finley and Nugent, 1995), prompted the inclusion of exact infant age at 
HR/HRV assessment as an independent variable in regression analyses to explore if timing of 
assessment factored into our findings. 
Maternal n-6 and n-3 families were included as independent variables. Fatty acids 
included in the n-6 series were γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), linoleic 
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acid (LA), and ARA. Fatty acids included in the n-3 series were α-linolenic acid (α-LA), EPA, 
and DHA. Percent change in HR and HRV from 2 weeks to 4 and 6 months of infant age was 
calculated and included in analyses as a dependent variable. Example calculation: [((HR at 6 
months of age – HR at 2 weeks of age)/HR at 2 weeks of age)*100].  
2.3 Results 
2.3.1 Fatty acid analysis 
 Table 2.2 provides relative wt% of n-6 and n-3 fatty acids in maternal erythrocytes at 
each timepoint during pregnancy (20, 24, 32, and 36 gestational weeks).  
 
2.3.2 Heart rate and heart rate variability changes over time 
 Infant HR and HRV during the first 6 months of life and changes between assessments (2 
weeks to 4 months, 4 months to 6 months, and 2 weeks to 6 months) are presented in Table 2.3. 
There was a significant decrease in HR from 2 weeks to 4 month (P ≤ 0.01), 4 month to 6 month 
(P ≤ 0.01), and 2 week to 6 month assessment (P ≤ 0.01) for an overall reduction of 17 bpm. The 
increase in SDNN was significant from 2 week to 4 month (P ≤ 0.01), trended from 4 month to 6 
Table 2.2 Relative wt% of n-6 and n-3 fatty acids in maternal erythrocytes during pregnancy1 
 20 GW2 24 GW 32 GW        36 GW 
n-6 fatty acids3     
     GLA  0.17 ± 0.03 0.17 ± 0.04   0.14 ± 0.02      0.15 ± 0.02 
     DGLA       1.61 ± 0.22 1.58 ± 0.23   1.59 ± 0.27      1.60 ± 0.26 
     LA     11.20 ± 1.78    10.83 ± 1.16 10.72 ± 0.87    10.06 ± 1.00 
     ARA     15.43 ± 1.28    14.98 ± 0.91 14.66 ± 0.72    14.11 ± 1.27 
n-3 fatty acids     
     α-LA  0.14 ± 0.05 0.14 ± 0.04   0.17 ± 0.04      0.17 ± 0.03 
     EPA  0.21 ± 0.10 0.29 ± 0.17   0.33 ± 0.25      0.31 ± 0.23 
     DHA  8.57 ± 1.12 8.53 ± 1.22   9.46 ± 1.51      9.51 ± 1.27 
1Fatty acids expressed as relative weight percentage (wt%); values are ?̅? ± SD (n = 11) 
2GW: gestational weeks 
3GLA: γ-linolenic acid; DGLA: dihomo-γ-linolenic acid; LA: linoleic acid; ARA: arachidonic acid; α-LA: α-
linolenic acid: EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid 
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month (P = 0.08), and was significant from 2 week to 6 month assessment (P ≤ 0.01) for an 
overall increase of 16 ms. The increase in ASDNN from 2 week to 4 month (P = 0.18) and 4 
month to 6 month assessment (P = 0.19) was not significant, but the overall increase (4 ms) from 
2 week to 6 month assessment reached statistical significance (P = 0.01). The increase in 
SDANN was significant from 2 week to 4 month (P ≤ 0.01), trended from 4 month to 6 month (P 
= 0.08), and was significant from 2 week to 6 month assessment (P ≤ 0.01) for an overall 
increase of 18 ms. 
 
 
2.3.3 Maternal fatty acid status and infant heart rate: simple linear regression 
 Significant and trending simple linear regression models describing the relationship 
between individual maternal n-6 and n-3 fatty acids during pregnancy and infant HR at the 2 
week, 4 month, and 6 month assessment are presented in Table 2.4.  
 Maternal DGLA at 20, 24, 32, and 36 gestational weeks was a positive predictor of 
infant HR at the 2 weeks assessment (r2 ≥ 0.42, P ≤ 0.03). Infant age at 2 week HR assessment 
was also significantly related to infant HR at 2 weeks (P = 0.04). At 24, 32, and 36 gestational  
Table 2.3 Infant heart rate and heart rate variability in the first 6 months of life1,2,3 
 HR, bpm SDNN, ms ASDNN, ms SDANN, ms 
2 weeks 146 ± 8     45 ± 11 25 ± 6  35 ± 10 
4 months 135 ± 5     56 ± 7 27 ± 4       47 ± 6 
6 months 128 ± 7  61 ± 10 29 ± 4 53 ±10 
 ------ Difference between timepoints ------ 
2 weeks to 4 months   -10 ± 24 10 ± 34   2 ± 2  12 ± 34 
4 months to 6 months     -7 ± 24  6 ± 3   2 ± 2   6 ± 3 
2 weeks to 6 months   -17 ± 24 16 ± 34    4 ± 24  18 ± 34 
1Values are ?̅? ± SD (n = 11) 
2HR: heart rate; bpm: beats per min; SDNN: standard deviation of filtered RR intervals over 24-h 
period; ms: milliseconds; ASDNN: mean of standard deviations of filtered RR intervals for all 5 
min segments of analysis; SDANN: standard deviation of means of filtered RR intervals for all 5 
min segments of analysis 
3HR, SDNN, ASDNN, and SDANN were significantly different (P ≤ 0.05) among participants  


























Table 2.4 Relationships for individual maternal erythrocyte n-6 and n-3 
fatty acids and infant heart rate: simple linear regression, n = 111,2,3  
  Infant heart rate, beats per min 
  2 week assessment 
Gestational week  β ± SE r2 P 
20 weeks     
     DGLA  23.8 ± 9.3 0.43    0.03 
24 weeks     
     DGLA  22.4 ± 8.9 0.42    0.03 
32 weeks     
     DGLA  20.5 ± 7.5 0.45    0.02 
36 weeks     
     DGLA  22.5 ± 7.2 0.52 ≤ 0.01 
Infant age4    1.4 ± 0.6 0.39    0.04 
  4 month assessment 
20 weeks      
     DHA  -2.7 ± 1.2 0.37     0.05 
24 weeks     
     ARA        3.5 ± 1.4 0.42     0.03 
     EPA   -20.4 ± 6.6 0.51  ≤ 0.01 
     DHA   -2.1 ± 1.2 0.28     0.09 
32 weeks     
     ARA    5.3 ± 1.5 0.59  ≤ 0.01 
     EPA   -14.7 ± 4.6 0.53  ≤ 0.01 
     DHA   -2.2 ± 0.8 0.45     0.02 
36 weeks     
     DGLA  11.9 ± 4.9 0.40     0.04 
     ARA    2.8 ± 0.9 0.45     0.02 
     EPA   -17.4 ± 4.0 0.68  ≤ 0.01 
     DHA   -2.8 ± 0.9 0.51  ≤ 0.01 
  6 month assessment 
20 weeks      
     DGLA  18.8 ± 8.2 0.37    0.05 
24 weeks     
     DGLA    17.6 ± 7.8 0.36    0.05 
     EPA  -24.0 ± 10.4 0.37    0.05 
32 weeks     
     DGLA  18.7 ± 5.8 0.53 ≤ 0.01 
36 weeks     
     GLA  186.2 ± 79.0 0.38    0.04 
     DGLA  20.3 ± 5.5 0.60 ≤ 0.01 
Infant age  -0.6 ± 0.3 0.31    0.08 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) reported 
2DGLA: dihomo-γ-linolenic acid; DHA: docosahexaenoic acid; ARA: arachidonic acid; 
EPA: eicosapentaenoic acid; GLA: γ-linolenic acid 
3DGLA, GLA, ARA: n-6 fatty acids; EPA, DHA: n-3 fatty acids 
4Exact infant age (days) at heart rate assessment 
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weeks, maternal ARA was a positive predictor of infant HR at the 4 month assessment (r2 ≥ 0.42, 
P ≤ 0.03). There was an inverse relationship between maternal EPA at 24, 32, and 36 weeks and 
infant HR at the 4 month assessment (r2 ≥ 0.51, P ≤ 0.01). Maternal DHA at each timepoint (20, 
24, 32, 36 gestational weeks) was inversely related to infant HR at the 4 month assessment (r2 ≥ 
0.28); this relationship was trending at 24 weeks (P = 0.09) and significant at 20, 32, and 36 
weeks (P ≤ 0.05). Maternal DGLA at 36 gestational weeks was also positively related to 4 month 
infant HR (r2 = 0.40, P ≤ 0.04). Significant predictors of infant HR at 6 months mirrored those 
related to HR at 2 weeks. At every timepoint (20, 24, 32, and 36 gestational weeks), maternal 
DGLA was positively related to infant HR at 6 months (r2 ≥ 0.36, P ≤ 0.05). At 36 gestational 
weeks, maternal GLA was positively related to infant HR at 6 months (r2 = 0.38, P = 0.04). 
Maternal EPA at 24 gestational weeks was an inverse predictor of 6 month infant HR (r2 = 0.37, 
P = 0.05). Infant age at 6 month assessment was also related to infant HR at 6 months (P = 0.08).  
2.3.4 Maternal fatty acid families, ratios, and infant heart rate: simple linear regression  
 Significant and trending simple linear regression models describing the relationship 
between maternal n-6 and n-3 fatty acid families, fatty acid ratios, and infant HR at 4 months of 
life are presented in Table 2.5. Maternal n-3 family at 20, 24, 32, and 36 gestational weeks 
(inverse; r2 ≥ 0.35, P ≤ 0.01), and maternal n-6:n-3 ratio (positive; r2 ≥ 0.27, P ≤ 0.10) were 
related to infant HR at the 4 month assessment. For both relationships, the greatest significance 
was observed at the 36 week timepoint (P ≤ 0.03). Maternal ratio of ARA:DHA at 24, 32, and 36 


















2.3.5 Maternal fatty acid status and infant heart rate: multiple regression 
  Significant and trending multiple regression models describing the relationship between 
individual maternal n-6 and n-3 fatty acids during pregnancy and infant HR at 2 weeks, 4 
months, and 6 months of life are presented in Table 2.6. Infant age at assessment was included in 
all multiple regression models for infant HR at 2 weeks and 6 months as it was a significant or 
trending variable (P = 0.04 and P = 0.08, respectively) in simple linear regression.  
 Maternal LA and DGLA at 24 gestational weeks and infant age were positively related to 
infant HR at the 2 week assessment (r2 ≥ 0.73, P = 0.02). Maternal DGLA and ARA at 24, 32, 
and 36 gestational weeks were inverse predictors of infant HR at the 4 month assessment (r2 ≥ 
0.59, P ≤ 0.03). Maternal EPA and ARA at 24 gestational weeks were significantly related to 
infant HR at 4 months (r2 ≥ 0.81, P ≤ 0.01) such that EPA was an inverse and ARA was a  
Table 2.5 Relationships for maternal erythrocyte n-6 and n-3 fatty acid families, 
fatty acid ratios, and infant heart rate: simple linear regression, n = 111 
  Infant heart rate, beats per min 
  4 month assessment 
Gestational week  β ± SE r2 P 
20 weeks     
     n-3 family2    -2.6 ± 1.1 0.37 0.05 
     n-6:n-3 families  4.6 ± 2.5 0.28 0.09 
24 weeks     
     n-3 family    -2.3 ± 1.0 0.35 0.06 
     n-6:n-3 families   4.5 ± 2.5 0.27 0.10 
     ARA:DHA   8.2 ± 3.6 0.38 0.05 
32 weeks     
     n-3 family  -2.1 ± 0.7 0.49                 0.02 
     n-6:n-3 family   5.7 ± 2.2 0.41                 0.03 
     ARA:DHA    10.7 ± 3.5 0.51              ≤ 0.01 
36 weeks     
     n-3 family  -2.5 ± 0.8 0.54              ≤ 0.01 
     n-6:n-3 families    6.7 ± 2.6 0.42 0.03 
     ARA:DHA  11.1 ± 3.7 0.50 0.02 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2n-3 family = α-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid (DHA); n-6 




Table 2.6 Relationships for individual maternal erythrocyte n-6 and n-3 fatty acids and 
infant heart rate: multiple regression, n = 111 
  Infant heart rate, beats per min 
  2 week assessment 
  Parameters2  Parameter estimates  Model estimates 
Gestational week    β ± SE P  r2 P 
24 weeks  LA  3.1 ± 1.5 0.07  0.73   0.02 
  DGLA  19.7 ± 8.1 0.04    
  Infant age3  1.0 ± 0.5 0.09    
  4 month assessment 
24 weeks  ARA  3.0 ± 0.9  ≤ 0.01  0.81 ≤ 0.01 
  EPA  -18.0 ± 4.5  ≤ 0.01    
  DGLA  8.7 ± 4.9 0.10  0.59   0.03 
  ARA  3.3 ± 1.3 0.03    
32 weeks  DGLA  7.3 ± 3.3 0.06  0.75 ≤ 0.01 
  ARA  5.3 ± 1.2  ≤ 0.01    
36 weeks  DGLA  11.5 ± 2.5  ≤ 0.01  0.87 ≤ 0.01 
  ARA  2.7 ± 0.5  ≤ 0.01    
  6 month assessment 
20 weeks  DGLA  16.5 ± 7.1 0.05  0.59   0.03 
  Infant age  -0.5 ± 0.3 0.07    
24 weeks  DGLA  14.9 ± 4.5  ≤ 0.01  0.84 ≤ 0.01 
  ARA  4.3 ± 1.5 0.02    
  Infant age  -0.1 ± 0.2  ≤ 0.01    
32 weeks  DGLA  15.8 ± 2.6  ≤ 0.01  0.93 ≤ 0.01 
  ARA  4.6 ± 1.0  ≤ 0.01    
  Infant age  -0.7 ± 0.1  ≤ 0.01    
36 weeks  DGLA  17. 6 ± 3.5  ≤ 0.01  0.88 ≤ 0.01 
  ARA  1.7 ± 0.7 0.05    
  Infant age  -0.6 ± 0.2  ≤ 0.01    
  EPA  -15.9 ± 6.5 0.04  0.61   0.02 
  Infant age  -0.66 ± 0.3 0.03    
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2LA: linoleic acid; DGLA: dihomo-γ-linolenic acid; ARA: arachidonic acid; EPA: eicosapentaenoic acid 
3LA, DGLA, ARA: n-6 fatty acids; EPA: n-3 fatty acid 
4Exact infant age (days) at assessment was included in all multiple regression models for infant heart rate at 2 
weeks  




positive predictor. Maternal DGLA and ARA at 24, 32, and 36 gestational weeks and infant age 
at assessment were associated with infant HR at the 6 month assessment (r2 ≥ 0.59, P ≤ 0.01); 
the association was positive for DGLA and ARA and inverse for age. Maternal EPA at 36 
gestational weeks and infant age at assessment were inversely related to infant HR at the 6 month 
assessment (r2 = 0.61, P = 0.02). 
2.3.6 Maternal fatty acid status and infant heart rate variability: simple linear regression  
 Significant and trending simple linear regression models describing the relationship 
between individual n-6 and n-3 maternal fatty acids and infant HRV during the first 6 months of 














   
Table 2.7 Relationships for individual maternal erythrocyte n-6 and 
n-3 fatty acids and infant SDNN: simple linear regression, n = 111,2,3  
  Infant SDNN, ms 
  2 week assessment 
Gestational week  β ± SE r2 P 
32 weeks     
     DGLA  -26.1 ± 11.0 0.38 0.04 
36 weeks     
     DGLA  -24.9 ± 11.7 0.34 0.06 
  4 month assessment 
24 weeks     
     α-LA     103.4 ± 46.6 0.35 0.05 
32 weeks     
     GLA  -285.1 ± 126.1 0.36 0.05 
     α-LA    105.4 ± 42.6 0.41 0.04 
36 weeks     
     LA  -3.8 ± 1.9 0.30 0.08 
  6 month assessment 
20 weeks     
     LA      -3.8 ± 1.3 0.49 0.02 
32 weeks     
     DGLA    -22.9 ± 9.2 0.41 0.03 
36 weeks     
     DGLA    -21.1 ± 9.9 0.33 0.06 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) 
are reported 
2SDNN: standard deviation of filtered RR intervals over 24-h period; DGLA: 
dihomo-γ-linolenic acid; GLA: γ-linolenic acid; α-LA: α-linolenic acid; LA: 
linoleic acid 






















There was an inverse relationship between maternal DGLA at 32 and 36 gestational 
weeks and infant SDNN at the 2 week assessment (r2 ≥ 0.34, P ≤ 0.06). Maternal DGLA at 24, 
32, and 36 gestational weeks was inversely associated with ASDNN at the 2 week assessment (r2 
≥ 0.27, P ≤ 0.09). 
Table 2.8 Relationships for individual and families of maternal 
erythrocyte n-6 and n-3 fatty acids and infant ASDNN: simple linear 
regression, n = 111,2 
  Infant ASDNN, ms 
  2 week assessment 
Gestational week  β ± SE r2 P 
24 weeks     
     DGLA  -13.6 ± 7.4 0.27 0.09 
32 weeks     
     DGLA  -13.9 ± 5.5 0.41 0.04 
36 weeks     
     DGLA  -11.6 ± 6.3 0.27 0.09 
  4 month assessment 
32 weeks     
     n-6 family3    -2.8 ± 1.3 0.34 0.06 
36 weeks     
     EPA   10.2 ± 4.9 0.32 0.07 
     DHA     2.0 ± 0.9 0.35 0.05 
     n-3 family     1.7 ± 0.8 0.35 0.05 
     n-6 family    -2.1 ± 1.0 0.32 0.07 
     n-6:n-3 families    -5.2 ± 2.4 0.35 0.06 
  6 month assessment 
20 weeks     
     α-LA       1.4 ± 0.65 0.35 0.06 
24 weeks     
     DGLA    -9.8 ± 5.2 0.28 0.09 
     EPA   14.1 ± 6.8 0.33 0.07 
32 weeks     
     DGLA  -10.6 ± 4.0 0.43 0.03 
36 weeks     
     EPA   10.1 ± 5.1 0.30 0.08 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) 
are reported 
2ASDNN: mean of standard deviations of filtered RR intervals for all 5 min 
segments of analysis; DGLA: dihomo-γ-linolenic acid; EPA: eicosapentaenoic 
acid; DHA: docosahexaenoic acid; α-LA: α-linolenic acid 
3n-6 family = γ-linolenic acid + DGLA + linoleic acid + arachidonic acid; n-3 
family = α-LA + EPA + DHA 
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At the 4 month assessment, infant SDNN was positively related to maternal α-LA at 24 
and 32 gestational weeks (r2 ≥ 0.35, P ≤ 0.05). Maternal GLA at 32 gestational weeks and LA at 
36 gestational weeks were significant (r2 = 0.36, P = 0.05) and trending inverse predictors (r2 = 
0.30, P = 0.08) of infant SDNN at the 4 month assessment, respectively. Maternal n-6 family at 
32 and 36 gestational weeks was a trending inverse predictor of infant ASDNN at the 4 month 
assessment (r2 ≥ 0.32, P ≤ 0.07). Maternal DHA, EPA, and n-3 family at 36 gestational weeks 
were all positively related to ASDNN at the 4 month assessment (r2 ≥ 0.32, P ≤ 0.07). Maternal 
n-6:n-3 ratio at 36 gestational weeks predicted infant ASDNN at the 4 month assessment 
(inverse; r2 = 0.35, P = 0.06). 
 Maternal LA and DGLA were inversely and α-LA was positively related to infant SDNN 
and ASDNN at the 6 month assessment; these relationships were observed at 20, 24, 32, and 36 
gestational weeks. There was a trending, positive relationship for maternal DGLA at 32 and 36 
gestational weeks and infant SDANN at the 6 month assessment (data not shown; r2 ≥ 0.29, P ≤ 
0.08). Maternal EPA at 24 and 36 gestational weeks was inversely associated with infant 
ASDNN at the 6 month assessment (r2 ≥ 0.28, P ≤ 0.07). 
2.3.7 Maternal fatty acid status and infant heart rate variability: multiple regression  
 Significant and trending multiple regression models describing the relationship between 
individual maternal n-6 and n-3 fatty acids during pregnancy and infant HRV during the first 6 
months of life are presented in Table 2.9. 
 A model including maternal LA and DGLA consistently had predictive value for infant 
HRV (r2 ≥ 0.49, P ≤ 0.04). This was observed at different timepoints (32 and 36 gestational 
weeks), at various HRV assessments (2 week and 6 month), and across HRV indices (SDNN, 
ASDNN, and SDANN). In each instance, LA and DGLA were both inversely related to the 
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respective HRV index. α-LA and DHA at 20 gestational weeks were also related to infant 
ASDNN at 6 months (r2 = 0.57, P = 0.04); both variables in the model were positive predictors. 
 
2.3.8 Maternal fatty acid status and percent change in infant heart rate and heart rate variability: 
simple linear regression  
 
 Significant and trending simple linear regression models describing the relationship 
between individual n-6 and n-3 fatty acids, families, and ratios and percent change in HR and 
HRV (SDANN) from the 2 week to the 4 and 6 month assessment are presented in Table 2.10.  
Table 2.9 Relationships for maternal erythrocyte n-6 and n-3 fatty acids and infant heart rate 
variability: multiple regression, n = 111 
  Heart rate variability, ms 
  Infant SDNN2, 2 week assessment 
  Parameters3,4  Parameter estimates  Model estimates 
Gestational week    β ± SE P  r2 P 
36 weeks  LA  -6.5 ± 2.6  0.04  0.63    0.02 
  DGLA  -33.9 ± 10.0  ≤ 0.01    
  Infant SDNN, 6 month assessment 
36 weeks  LA  -5.8 ± 2.1  0.03  0.65 ≤ 0.01 
  DGLA    -29.1 ± 8.2  ≤ 0.01    
  Infant ASDNN, 2 week assessment 
32 weeks  LA  -3.7 ± 1.3  0.02  0.72 ≤ 0.01 
  DGLA    -16.3 ± 4.2  ≤ 0.01    
36 weeks  LA  -4.9 ± 0.8  ≤ 0.01  0.89 ≤ 0.01 
  DGLA    -18.3 ± 2.9  ≤ 0.01    
  Infant ASDNN, 6 month assessment 
20 weeks  α-LA    82.9 ± 25.7  ≤ 0.01  0.57   0.04 
  DHA    2.1 ± 1.1  0.10    
36 weeks  LA    -2.1 ± 1.2  0.10  0.49   0.07 
  DGLA  -11.5 ± 4.5  0.03    
  Infant SDANN, 6 month assessment 
36 weeks  LA  -6.1 ± 2.2  0.03  0.63    0.02 
  DGLA  -28.3 ± 8.5  0.01    
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2SDNN: standard deviation of filtered RR intervals over 24-h period; ASDNN: mean of standard deviations of 
filtered RR intervals for all 5 min segments of analysis; SDANN: standard deviation of means of filtered RR 
intervals for all 5 min segments of analysis 
3LA: linoleic acid; DGLA: dihomo-γ-linolenic acid; α-LA: α-linolenic acid 




Table 2.10 Relationships for individual and families of maternal erythrocyte n-6 and n-3 fatty acids 
and percent change in infant heart rate and heart rate variability: simple linear regression, n = 111,2 
  Infant heart rate, bpm 
  % change from 2 weeks to 4 month assessment 
Gestational week  β ± SE r2 P 
20 weeks     
     n-6:n-3 families3  4.9 ± 2.6 0.28   0.09 
24 weeks     
     ARA  4.5 ± 1.3 0.58                              ≤ 0.01 
32 weeks     
     ARA  5.1 ± 1.8 0.48    0.02 
36 weeks     
     ARA  2.6 ± 1.1 0.38    0.04 
     ARA:DHA  9.5 ± 4.7 0.32    0.07 
  % change from 2 weeks to 6 month assessment 
24 weeks     
     ARA  2.2 ± 1.0 0.36    0.05 
32 weeks     
     ARA  3.4 ± 1.1 0.52                              ≤ 0.01 
36 weeks     
     ARA  1.4 ± 0.8 0.28                                 0.09 
  SDANN, ms4 
  % change from 2 weeks to 4 month assessment 
32 weeks     
     ARA  -31.5 ± 15.0 0.33   0.06 
  % change from 2 weeks to 6 month assessment 
20 weeks     
     DHA  13.0 ± 6.6 0.31    0.08 
     n-3 family  12.4 ± 6.4 0.30    0.08 
     ARA:DHA  -75.3 ± 25.3 0.50    0.02 
24 weeks     
     ARA     -15.3 ± 8.3 0.28    0.09 
32 weeks     
     ARA     -28.4 ± 7.9 0.59                              ≤ 0.01 
     n-6 family     -16.9 ± 8.4 0.31    0.07 
36 weeks     
     ARA     -12.0 ± 5.7 0.33    0.07 
     DHA  11.3 ± 5.9 0.29    0.09 
     ARA:DHA   -47.3 ± 23.1 0.32    0.07 
     n-6 family     -15.2 ± 5.9 0.42    0.03 
     n-3 family    9.8 ± 5.0 0.30    0.08 
     n-6:n-3 families   -32.4 ± 14.9 0.34    0.06 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2Example percent change calculation: [((6 month heart rate - 2 week heart rate)/2 week heart rate)*100]. 
3n-6 family = γ-linolenic acid + dihomo-γ-linolenic acid + linoleic acid + arachidonic acid (ARA); n-3 family = α-
linolenic acid + eicosapentaenoic acid + docosahexaenoic acid (DHA) 
4SDANN: standard deviation of means of filtered RR intervals for all 5 min segments of analysis 
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Percent change in HR from the 2 week to the 4 month assessment was positively related 
to maternal n-6:n-3 ratio at 20 gestational weeks (r2 = 0.28, P = 0.09). Maternal ARA at 24, 32, 
and 36 gestational weeks was a significant predictor of change in percent HR from the 2 week to 
the 4 month assessment (r2 ≥ 0.38, P ≤ 0.04); the relationship was positive at all timepoints. 
Maternal ARA:DHA ratio at 36 gestational weeks was a positive predictor of percent change in 
HR at the 4 month assessment (r2 ≥ 0.32, P = 0.07). 
 In examining percent change in HR from the 2 week to the 6 month assessment, maternal 
ARA at 24, 32, and 36 gestational weeks was a trending or significant predictor (r2 ≥ 0.36, P ≤ 
0.09). This relationship was positive and most significant at 32 gestational weeks (P = 0.02). 
Percent change in SDANN from the 2 week to the 4 month assessment was inversely associated 
with maternal ARA at 32 gestational weeks (r2 = 0.33, P = 0.06). There was a positive 
relationship between maternal n-6 family at 20 gestational weeks (data not shown; r2 = 0.31, P = 
0.08) and percent change in SDNN at the 4 month assessment. Maternal LA and GLA at 20 
gestational weeks were independent, inverse predictors of percent change in ASDNN at the 4 
month assessment (data not shown; r2 = 0.35, P = 0.05 and r2 = 0.30, P = 0.08, respectively). 
Maternal DHA and n-3 family at 20 gestational weeks were independent, positive 
predictors of percent change in infant SDANN from the 2 week to the 6 month assessment (r2 = 
0.30 – 0.31, P = 0.08). Maternal ARA:DHA at 20 gestational weeks was inversely associated 
with percent change in infant SDANN at 6 months (r2 = 0.50, P = 0.02). Percent change in infant 
SDANN at the 6 month assessment was inversely associated with maternal ARA at 24 (r2 = 0.28, 
P = 0.09) and 32 gestational weeks (r2 = 0.59, P ≤ 0.01) and maternal n-6 family at 32 
gestational weeks (r2 = 0.31, P = 0.07). At 36 gestational weeks, maternal ARA, n-6 family, 
ARA:DHA ratio, and n-6:n-3 family ratio were all inversely related to percent change in infant 
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SDANN from the 2 week to the 6 month assessment (r2 = 0.32 – 0.42, P ≤ 0.07). Maternal DHA 
and the n-3 family were positively related to percent change in SDANN at the 6 month 
assessment (r2 = 0.29 – 0.30, P ≤ 0.09). 
2.4. Discussion 
2.4.1 Infant heart rate and heart rate variability are age-dependent 
 In the current study, HR decreased and HRV increased with advancing infant age, a 
finding which is consistent with previous reports (Finley and Nugent 1995; Massin and von 
Bernuth, 1997). Decreased HR and increased HRV are hallmarks of health, although there are 
certain populations for whom this interpretation is inappropriate (Stein et al., 2005). For the 
current population, decreased HR and increased HRV are healthful attributes. Thus, independent 
variables that are inversely related to HR and/or positively related to HRV may have a role in 
accelerating autonomic maturation. 
2.4.2 Cautions for data interpretation 
Caution should be used when interpreting parameter and model estimates for the current 
data. For example, parameter estimates for maternal DGLA were consistently larger than those 
for maternal ARA. This is likely an artifact of low maternal DGLA relative to ARA. This 
example is also applicable to parameter estimates associated with GLA, α-LA, and EPA. Thus, 
the nature of the relationship (inverse or positive) should be the focus of the current data rather 
than the parameter or model estimate.  
The percent change calculation required the assumption that the 2 week HR and HRV 
assessment was similar among participants, although this assumption was not met. As such, this 
calculation may not accurately represent HR and HRV maturation from 2 weeks to 6 months of 
infant age and should be interpreted with care. 
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2.4.3 Maternal fatty acid status during pregnancy is related to infant autonomic development 
 This observational study is the first to link maternal fatty acid status during pregnancy to 
infant HR and HRV in the first 6 months of life. Previous research examined the effects of 
maternal n-3 LCPUFA supplementation on fetal HR and HRV (Gustafson et al., 2013) and of 
postnatal n-3 LCPUFA supplementation on infant HR and HRV (Lauritzen et al., 2008; Pivik et 
al., 2009; Colombo et al., 2011). Current findings are in line with these reports, which evidenced 
a HR-lowering and HRV-increasing effect of n-3 LCPUFA, especially DHA. Higher maternal n-
3 fatty acid status, especially DHA, was associated with reduced infant HR and increased HRV, 
characteristics of a mature, robust autonomic nervous system. Conversely, higher maternal n-6 
fatty acids and/or n-6:n-3 ratio were related to increased infant HR and reduced HRV. By 
calculating percent change in HR and HRV, we also observed evidence for maternal n-3 fatty 
acid status to accelerate postnatal autonomic development, although there were limitations to this 
calculation, as noted above.  
Interestingly, we observed an unfavorable association between maternal n-6 fatty acids 
infant HR and HRV more often than we observed a beneficial association for n-3 fatty acids. 
Thus, it is likely n-3 LCPUFA intake improves HR and HRV: 1) indirectly, by n-6 fatty acid 
displacement, and 2) directly, by biological actions of n-3 fatty acids in vivo, such as autonomic 
modulation. 
 Infant ASDNN, also known as SDNN-index, was the most sensitive time-domain HRV 
index to maternal fatty acids during pregnancy in the current study. Lauritzen et al. (2008) did 
not observe changes in infant HRV, including ASDNN, after postnatal intervention with fish oil. 
However, Gustafson et al. (2013) reported fetuses whose mothers were supplemented with DHA 
during pregnancy had higher metrics of very-low frequency and low frequency power at 24, 32, 
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and 36 gestational weeks than those whose mothers received a placebo. These frequency-domain 
metrics of HRV are highly, independently correlated (r2 ≥ 0.89) with ASDNN (Bigger Jr. et al., 
1992) and, as such, are consistent with our data. 
 Our data suggests the developing autonomic nervous system is sensitive to maternal fatty 
acid status as early as 20 gestational weeks, although fatty acids at 32 and 36 gestational weeks 
were the most significant predictors of infant HR and HRV. The number of myelinated vagal 
(parasympathetic) fibers rapidly increases around 24 gestational weeks and throughout the first 
postnatal year (Pereyra et al., 1992) with the greatest increases occurring from 30 – 32 
gestational weeks to 6 months of age (Sachis et al., 1982). Thus, significant or trending 
predictors observed at earlier timepoints (20 and 24 gestational weeks) were likely interacting 
with the fetal sympathetic nervous system while those observed at 32 and 36 gestational weeks 
were also a reflection of interactions with the developing parasympathetic nervous system. 
 It has previously been proposed that 3 – 5 months of infant age is an appropriate time to 
assess if n-3 LCPUFAs have a programming effect on cardiovascular outcomes, including HR 
and HRV (Pivik et al., 2009). However, maternally-influenced group differences in HR and 
HRV, including differences resulting from maternal n-3 LCPUFA intervention, have been 
observed in utero (May et al., 2010; Gustafson et al., 2013). In the current study, relationships 
between maternal erythrocyte fatty acids and infant HR and HRV were clinically apparent as 
early as 2 weeks and persisted until 6 months of infant age, indicating programming effects of 
the autonomic nervous system may be observed in neonatal life. 
2.5 Limitations 
 This study was primarily limited by sample size (n = 11). Much of the presented data 
existed as statistical trends. However, patterns and themes were consistently observed and are 
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expected to be stronger in larger samples with more statistical power. Further, sample size 
limited inclusion of factors other than maternal fatty acid concentrations and exact infant age at 
HR/HRV assessment in multiple regression models due to loss of statistical power. However, for 
study enrollment, participants were required to meet strict inclusion and exclusion criteria, 
defined above. These criteria ensured the study participants (mothers) had similar characteristics 
to minimize the influence of external factors on outcomes.  
2.6 Conclusion 
 We have demonstrated that maternal fatty acid status during pregnancy is related to infant 
HR and HRV, reflecting autonomic development and cardiac-autonomic integration. These data 
confirm that the developing autonomic nervous system is sensitive to nutritional programing and 
build upon existing literature evidencing a role for n-3 fatty acids, especially DHA, in 
accelerating autonomic development.  
HR and frequency-domain metrics of HRV at 4 months of age are reliable markers of 
their respective trajectories throughout life, up to 4 years of age (Bar-Haim et al., 2000). 
Accordingly, we speculate that maternal nutrition during pregnancy affects autonomic 
development, which is apparent in infancy and extends to later life measures. Specifically, 
maternal intake of n-3 fatty acids and a lower n-6:n-3 ratio accelerates autonomic maturation. 
While this hypothesis is a bold extrapolation of previous and current data, it has scientific merit 
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CHAPTER 3. MATERNAL INFLAMMATORY STATUS DURING PREGNANCY IS 
RELATED TO INFANT HEART RATE AND HEART RATE VARIABILITY 
 
3.1 Introduction 
The fetal origins hypothesis is the well-accepted observation that the intrauterine 
environment, especially nutritional status (Rinaudo and Lamb, 2008), can program neonatal 
outcome with lifetime health and developmental consequences (Barker, 1992). Alterations in the 
fetal environment, including a stimulus or an insult during a critical developmental period, can 
result in adaptations, including structural, physiological, and metabolic changes, potentially 
predisposing the fetus to adverse outcomes, including chronic diseases, in later life (Barker, 
1995; Muhlhausler and Ong, 2011). Adults who were prenatally exposed to famine have less 
DNA methylation of certain genes than their unexposed, same-sex siblings (Heijmans et al., 
2008). This study was among the first to provide empirical support for the fetal origins 
hypothesis. 
 The fetal autonomic nervous system is sensitive to programming by maternal factors, 
including nutrition (Gustafson et al., 2013) and exercise (May et al., 2010) during pregnancy. It 
has also been suggested that this developing system can be programmed by inflammatory stress, 
although this is largely speculative (Karrow, 2006). It follows then that fetal autonomic 
sensitivity to inflammation may be a common factor underlying those previous observations.  
Central nervous system function depends on pro- and anti-inflammatory reactions during 
development (Pousset et al., 1997; Zou et al., 1998; Dziegielewska et al., 2000; Vela et al., 2002; 
Farkas et al., 2003). However, some pro-inflammatory molecules can be neurotoxic, depending 
on their concentrations and the developmental stage at which the fetus is exposed (Nelson and 
Willoughby, 2002). Thus, it is plausible that high circulating concentrations of these molecules 
during critical developmental periods could alter the autonomic nervous system (Karrow, 2006).  
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Endocannabinoids, endogenous fatty acid derivatives, are ligands for cannabinoid 
receptors which are densely expressed in the brain (Glass et al., 1997). Endocannabinoids have a 
role in modulating inflammation (De Petrocellis et al., 2000) and autonomic function (reviewed 
by Pertwee, 1997). The relationship between circulating endocannabinoids, the placenta, and the 
fetus prompted the recent hypothesis that endocannabinoids function as a long-distance signaling 
system underlying fetal programming (Keimpema et al., 2013). 
Autonomic activity is readily assessed through analysis of heart rate (HR) and heart rate 
variability (HRV). Currently, there is a body of literature exploring the effects of inflammation, 
assessed as circulating cytokines, on HRV, reviewed by Haensel et al. (2008). The authors 
determined that, in healthy adults and adults with cardiovascular diseases, HRV was inversely 
correlated with inflammatory biomarkers, including interleukin (IL)-6 and C-reactive protein 
(CRP). Studies examining cannabis use (Δ9-tetrahydrocannabinol, THC) evidence a HR-
lowering and HRV-increasing effect (Benowitz and Jones 1981; Kunos et al., 2000; Pacher et al., 
2008; Schmid et al., 2010). Endocannabinoids are endogenously-derived THC counterparts that 
activate cannabinoid receptor type 1 (CB1) and 2 (CB2). HRV effects have not been assessed as 
they relate to endocannabinoid concentrations, to the best of our knowledge.  
The effect of intrauterine exposure to inflammatory mediators on infant HR and HRV has 
not been previously explored. Accordingly, the aim of this observational study was to examine 
the relationship between maternal inflammatory status during pregnancy and infant HR and HRV 
during the first 6 months of life. Inflammatory status was assessed as endocannabinoids, 
cytokines (IL-6, tumor necrosis factor-α [TNF-α]), adipokines (adiponectin), and acute phase 





All procedures involving human subjects were approved by the Louisiana State 
University AgCenter, Woman’s Hospital, and Pennington Biomedical Research Center 
Institutional Review Boards.  
3.2.1 Participants 
 Participants enrolled in a larger study (LA Moms and Babies Study [LAMBS] for 
Nutrition and Growth) were invited to enroll in the current study. For the larger study, women 
were recruited from an obstetrics and gynecology clinic, Associates in Women’s Health, at 
Woman’s Hospital in Baton Rouge, LA. Women were invited to participate in the study if they: 
were 18 – 35 years of age, had a singleton pregnancy, were between 17 and 20 gestational 
weeks, and had a pre-pregnancy body mass index of 25.0 – 29.9. Exclusion criteria included: 
history or current diagnosis of high blood pressure, high blood lipids, kidney disease, liver 
disease, polycystic ovarian syndrome, HIV, or diabetes mellitus (type 1, type 2, or gestational); a 
first degree relative diagnosed with diabetes mellitus (type 1 or type 2); uncontrolled thyroid 
disorder; smoking in the past 6 months; parity > 5; pre-term birth (≤ 37 gestational weeks); 
positive test for group B streptococcus, syphilis, or Hepatitis B; or pregnant or lactating within 
the previous 6 months.  
From the LAMBS study, seventeen women were approached between 37 gestational 
weeks and 1 week after delivery and invited to participate in the current study. Overall, thirteen 
mother-infant pairs completed informed consent; one mother-infant pair was excluded from 
analysis due to infant diagnosis of congenital heart defects at 6 months of age and one mother-
infant pair was excluded from the study for failure to comply with study protocol. The final 
sample size was n = 11. Maternal and infant characteristics are presented in Table 2.1. 
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3.2.2 Blood collection 
Blood collections occurred prior to informed consent for the current study. In the 
LAMBS study, informed consent contained an optional clause for collected blood samples to be 
used in future, ancillary studies. All women consented for the current study had consented to the 
clause. Maternal blood samples were collected at 17-20, 24, 32, and 36 gestational weeks. 
Maternal blood (~10 mL) was sampled from the antecubital vein and collected in EDTA-
containing tubes. Umbilical cord blood (~5-10 mL) was sampled from the venous vein into 
EDTA-containing tubes at delivery. Plasma and serum were individually separated from 
erythrocytes by centrifugation (2600 × g at 4°C for 10 min), portioned, and immediately stored at 
-80°C until analysis. 
3.2.3 Endocannabinoid analysis 
As previously described (Williams et al., 2007; Wood et al., 2008), a known amount of 
deuterated internal standard mixture was added to thawed plasma. Plasma proteins were 
precipitated with chilled acetone and PBS (3:1) and internal standard then centrifuged (14,000 × 
g, 5 min, 4°C). Acetone was evaporated from the recovered supernatant under nitrogen. Liquid-
liquid phase extraction was performed on the remaining supernatant with PBS, methanol, and 
chloroform (1:1:2, by volume). The two phases were separated by centrifugation (14,000 × g, 5 
min, 4°C), and the lower organic layer was quantitatively recovered and evaporated to dryness 
under nitrogen. Dried lipid extracts were reconstituted in ethanol, vortexed, sonicated, and 
centrifuged (14,000 × g, 5 min, 4°C). 
Multiple reaction monitoring (MRM) of the endocannabinoid metabolome and the 
corresponding deuterated internal standards was performed as previously described (Williams et 
al., 2006; Williams et al., 2007) using a TSQ Quantum Ultra triple quadrupole mass spectrometer 
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(Thermo Electron, San Jose, CA) with an Agilent 1100 HPLC on the front end (Agilent 
Technologies, Wilmington, DE). Chromatographic separation was achieved using an Agilent 
Zorbax SB-CN column (2.1 × 50 mm, 5 μm) with gradient elution using 10 mM ammonium 
acetate and 100% methanol. Eluted peaks were ionized via atmospheric pressure chemical 
ionization in MRM mode. Deuterated internal standards were used for each analyte’s standard 
curve and their concentrations per mL of plasma were determined.   
3.2.4 Cytokine, adipokine, and acute phase reactant analysis 
Serum was utilized for analysis of cytokines, adipokines, and acute phase reactants. High 
sensitivity CRP was determined by chemiluminescent immunoassay (Immulite 2000TM, Siemens 
Healthcare Diagnostics, Deerfield, IL, USA), TNF-α and IL-6 by immunoassay (Luminex 
100TM, Luminex Corp., Austin, TX, USA), and adiponectin by radioimmunoassay (Linco 
Research Inc., St Charles, MO, USA). 
3.2.5 Infant heart rate and heart rate variability analysis 
 Continuous ambulatory electrocardiograph monitoring was conducted in infants for a 24 
h period at 2 weeks, 4 months, and 6 months of age with Holter monitors (DigiTrak XT; Philips, 
Amsterdam, NL). Recordings were conducted in the participant’s home. Mothers were 
encouraged to allow infants to engage in normal activities, advised to dress infants in a tight-
fitting onesie to minimize choking hazard, and cautioned against immersing infants in water 
during the recording periods. Recordings were analyzed by a certified technician with aid of a 
diagnostic software program (Philips Zymed Holter 1810 Series, Version 2.9.4) to identify and 
label each QRS complex as normal or abnormal based on morphology and timing. Only QRS 
complexes with normal morphology were used in calculating HR and HRV measures. All 
recordings contained ≥ 23.5 h of analyzable data. 
91 
 
 Mean HR was calculated as the average of all filtered RR intervals over the 24 h 
recording period. Three time-domain measures reflecting HRV were calculated: 1) SDNN, the 
standard deviation of filtered RR intervals over the 24 h recording period; 2) SDANN, the 
standard deviation of the means of all filtered RR intervals for all 5 min segments of the analysis; 
and 3) ASDNN (also known as SDNN-index), the mean of the standard deviations of all filtered 
RR intervals for all 5 min segments of the analysis.  
Interpretation and application of each time-domain HRV index are outlined in Task 
Force, 1996; Stein and Kleiger, 1999; and Sztajzel, 2004. Each time-domain index is highly 
correlated (r2 ≥ 0.89) to a frequency-domain metric (Bigger Jr. et al., 1992). Time-domain 
analysis quantitates variability while frequency-domain analysis addresses the underlying 
rhythms responsible for that variability (Stein et al., 1994).  
When assessed over a 24 h period, SDNN is an overall metric of HRV which is 
correlated to total power (r2 = 0.96) and reflects all cyclic components contributing to variation, 
including short-term high frequency variations and long-term low frequency components (Task 
Force, 1996; Sztajzel, 2004). Total power, the total variance in the signal, is calculated as the 
summation of high frequency, low frequency, very-low frequency, and ultra-low frequency 
metrics (Stein and Kleiger, 1999). As such, SDNN encompasses parasympathetic- and 
sympathetically-modulated variations in HR. SDANN, which is strongly correlated to the ultra-
low frequency metric (r2 = 0.96), is an estimate of long-term components of HRV and represents 
variation due to low frequency activities, such as physical activity, postural changes, and 
circadian rhythm (Bigger Jr. et al., 1992; Task Force, 1996; Sztajzel, 2004). ASDNN is 
correlated to very-low frequency (r2 = 0.90) and low frequency metrics (r2 = 0.89) and, thus, 
represents variations related to the thermoregulatory, peripheral vasomotor, and/or renin 
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angiotensin systems, as well as oscillatory rhythms of the baroreceptor system (Bigger Jr. et al., 
1992; Stein and Kleiger, 1999).  
3.2.6 Statistical analyses and calculations 
Statistical analyses were performed using SAS, by SAS Institute, Inc., version 9.4 (Cary, 
NC). For all measures, level of significance was set at ≤ 0.05 and trends were ≤ 0.10. Repeated 
measures of HR and HRV at the 2 week, 4 month, and 6 month assessment were analyzed using 
a randomized block design with factors infant (blocking factor) and time. Individual one-tailed t-
tests were used to describe changes in HR and HRV between timepoints (2 weeks to 4 months; 4 
months to 6 months; 2 weeks to 6 months).  
Simple linear and multiple (backward stepwise) regression analyses were performed to 
explore associations between maternal erythrocyte fatty acids (independent or predictor 
variables) during pregnancy and infant HR and HRV (dependent variables). In most cases, it was 
impossible to assess infant HR/HRV at exactly 2 weeks, 4 months, or 6 months of age. This, 
combined with HR and HRV changes that are a natural reflection of advancing age during the 
first 6 months of life (Finley and Nugent, 1995), prompted the inclusion of exact infant age at 
HR/HRV assessment as an independent variable in regression analyses to explore if timing of 
assessment factored into our findings. 
Endocannabinoid data are limited to those related to the n-6 (AEA) and n-3 (EEA, EPEA, 
and DHEA) fatty acids. Endocannabinoids related to the n-3 fatty acid family were combined 
and included as an independent variable; this variable is referred to as “n-3 family” and includes 






3.3.1 Endocannabinoid analysis 
 Maternal and venous cord plasma n-6 and n-3 endocannabinoids are presented in Table 
3.1. Eleven N-acyl-ethanolamine and acyl-glycerol species recognized as constituents of the 
endocannabinoid metabolome were simultaneously analyzed by the LC-MS/MS-based 
metabolomics approach (Williams et al., 2007; Wood et al., 2008). Standard curves for each 
analyte were linear with regression values ≥ 0.98. Extraction efficiencies, determined by 
comparing area ratios of each extracted BSA analyte to the un-extracted standards in ethanol 
(Williams et al., 2007), were ≥ 83% except for DHEA and acyl-glycerol species. Of the eleven 
endocannabinoid-related metabolites studied, AEA, PEA, OEA, and DHEA were readily 
detected. EPEA and EEA were moderately detected and the acyl-glycerols were not detected.  
3.3.2 Cytokine, adipokine, and acute phase reactant analysis 
 Maternal and venous cord serum cytokines, adipokine, and acute phase reactant 
concentrations are presented in Table 3.1. Adiponectin and CRP were readily detected and TNF-
α was moderately detected (≥ 82%) in maternal serum at 20, 24, 32, and 36 gestational weeks. 
Maternal serum IL-6 was marginally detected (≤ 28%) at 20, 24, 32, and 36 gestational weeks 
and excluded from statistical analyses. In venous cord serum, adiponectin, TNF-α, and IL-6 were 
moderately detected (≥ 64%). Venous cord serum CRP was marginally detected (≤ 28%) in 
venous cord serum and excluded from statistical analysis. 
3.3.3 Heart rate and heart rate variability changes over time  
Infant HR and HRV during the first 6 months of life and changes between assessments (2 weeks 
to 4 months, 4 months to 6 months, and 2 weeks to 6 months) are presented in Table 2.3. There 




 (P ≤ 0.01), and 2 week to 6 month assessment (P ≤ 0.01) for an overall reduction of 17 bpm. 
The increase in SDNN was significant from the 2 week to 4 month (P ≤ 0.01), trended from the 4 
month to 6 month (P = 0.08), and was significant from the 2 week to 6 month assessment (P ≤ 
0.01) for an overall increase of 16 ms. The increase in ASDNN from the 2 week to 4 month (P = 
0.18) and 4 month to 6 month assessment (P = 0.19) was not significant, but the overall increase 
(4 ms) from the 2 week to 6 month assessment reached statistical significance (P = 0.01). The 
increase in SDANN was significant from the 2 week to 4 month (P ≤ 0.01), trended from 4 
month to 6 month (P = 0.08), and was significant from the 2 week to 6 month assessment (P ≤ 
0.01) for an overall increase of 18 ms. 
 
 
Table 3.1 Maternal and venous cord plasma n-6 and n-3 endocannabinoids and serum cytokines, 
adipokines, and acute phase reactants1 
 20 GW2 24 GW 32 GW 36 GW Delivery 
Endocannabinoids, ng/mL3      
     AEA  0.24 ± 0.076 0.17 ± 0.096 0.16 ± 0.08 0.30 ± 0.405 0.42 ± 0.196 
     EEA 0.07 ± 0.03  0.07 ± 0.03 0.10 ± 0.08  0.11 ± 0.14 0.06 ± 0.026 
     EPEA  0.30 ± 0.205 0.27 ± 0.057  0.35 ± 0.336 0.31 ± 0.186 0.33 ± 0.086 
     DHEA 0.41 ± 0.15 0.50 ± 0.287 0.59 ± 0.38  0.66 ± 0.59 0.78 ± 0.226 
Cytokines, pg/mL      
     IL-6 n/a8 n/a n/a n/a 13.8 ± 10.15 
     TNF-α  9.8 ± 4.86 9.4 ± 3.56  8.9 ± 3.56    9.1 ± 3.16    28.3 ± 7.65 
Adipokine, µg/mL      
     Adiponectin 7.8 ± 3.5   6.5 ± 2.4 5.9 ± 2.6    5.9 ± 3.6     28.3 ± 8.54 
Acute phase reactant, mg/L      
     CRP   10.2 ± 6.4  17.9 ± 27.2 9.6 ± 6.7    7.6 ± 4.9 n/a 
1Values are ?̅? ± SD; n = 11, unless otherwise noted 
2GW: gestational weeks; Delivery indicates venous cord plasma/serum collected at birth 
3AEA: anandamide (n-6 related); EEA: eicosanoyl ethanolamine (n-3 related); EPEA: eicosapentaenoyl ethanolamine (n-3 
related); DHEA: docosahexaenoyl ethanolamine (n-3 related); IL-6: interleukin-6; TNF-α: tumor necrosis factor-α; CRP: C-
reactive protein 
4n = 7; 5n = 8; 6n = 9; 7n = 10; 8n/a indicates the analyte was marginally detected (≤ 28%) and excluded from statistical analyses 
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3.3.4 Maternal endocannabinoids and infant heart rate: simple linear regression  
 Significant (P ≤ 0.05) and trending (P ≤ 0.10) simple linear regression models describing 
relationships for individual, families, and ratios of maternal endocannabinoids during pregnancy 
and infant HR in the first 6 months of life are presented in Table 3.2. 
 Maternal EPEA at 24 gestational weeks was related (inverse; r2 = 0.32; P = 0.09) to 
infant HR at the 2 week assessment. Maternal n-3 endocannabinoid family at 24 gestational 
weeks was also inversely related to 2 week infant HR (r2 = 0.38; P = 0.05). Maternal AEA:n-3 
family ratio at 24 gestational weeks was positively related to infant HR at the 2 week assessment 
(r2 = 0.38; P = 0.08). There was a significant relationship between infant age at assessment and 2 
week HR (positive; r2 = 0.39; P = 0.04). 
 At several timepoints in pregnancy (24, 32, 36 gestational weeks) and in cord plasma at 
delivery, EPEA was inversely related to infant HR at 4 months of age; this relationship was 
trending at 36 weeks (r2 = 0.38; P = 0.08) but significant at 24 and 32 gestational weeks and 
delivery (r2 ≥ 0.46; P ≤ 0.03). Maternal DHEA and maternal n-3 endocannabinoid family at 24 
and 32 gestational weeks and at delivery were also inversely related to 4 month infant HR (r2 ≥ 
0.33; P ≤ 0.06 and r2 ≥ 0.33; P ≤ 0.07, respectively). 
 Maternal AEA at 20 gestational weeks (r2: 0.41; P = 0.06) and maternal AEA:DHEA (r2 
= 0.38; P = 0.08) at delivery were positive predictors of infant HR at the 6 month assessment. 
There were inverse relationships for maternal n-3 family at 24, 36 gestational weeks and 6 month 





Table 3.2 Relationships for individual, families, and ratios of maternal n-6 and n-3 
endocannabinoids and infant heart rate: simple linear regression1,2  
  Infant heart rate, beats per min 
  2 week assessment 
Gestational week  n β ± SE r2 P 
24 weeks      
     EPEA  10    -84.8 ± 43.6 0.32 0.09 
     n-3 family  11    -13.7 ± 5.9 0.38 0.05 
     AEA:n-3 family    9     53.4 ± 25.9 0.38 0.08 
Infant age3  11       1.4 ± 0.6 0.39 0.04 
  4 month assessment 
24 weeks      
     EPEA  10    -66.4 ± 25.5 0.46 0.03 
     DHEA  11    -10.1 ± 4.8 0.33 0.06 
     n-3 family  11      -7.8 ± 3.7 0.33 0.07 
32 weeks      
     EPEA    9    -11.6 ± 3.6 0.60 0.02 
     DHEA  10    -11.1 ± 2.7 0.67    ≤ 0.01 
     n-3 family  11      -5.3 ± 1.3 0.64    ≤ 0.01 
36 weeks      
     EPEA    9    -17.8 ± 8.5 0.38 0.08 
Delivery4      
     EPEA    9    -44.9 ± 14.4 0.58 0.02 
     DHEA    9    -18.2 ± 4.7 0.68    ≤ 0.01 
     n-3 family    9    -14.0 ± 3.2 0.73    ≤ 0.01 
  6 month assessment 
20 weeks      
     AEA    9     63.7 ± 28.7 0.41 0.06 
24 weeks      
     EEA  11  -136.1 ± 69.0 0.30 0.08 
     EPEA  10    -92.5 ± 32.0 0.51 0.02 
     n-3 family  11    -10.7 ± 5.1 0.33 0.07 
32 weeks      
     EEA  11    -47.9 ± 21.6 0.35 0.05 
     EPEA    9    -12.4 ± 5.8 0.39 0.07 
36 weeks      
     n-3 family  11      -4.9 ± 2.5 0.30 0.08 
Delivery      
     AEA:DHEA    9      14.9 ± 7.3 0.38 0.08 
Infant age  11      -0.6 ± 0.3 0.31 0.08 
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2EPEA: eicosapentaenoyl ethanolamine; n-3 family: eicosanoyl ethanolamine (EEA) + EPEA + 
docosahexaenoyl ethanolamine (DHEA); AEA: anandamide (n-6 related) 
3Exact infant age (days) at heart rate assessment 
4Venous cord plasma collected at delivery 
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both independent, inverse predictors of infant HR at the 6 month assessment (r2 ≥ 0.30; P ≤ 0.08 
and r2 ≥ 0.39; P ≤ 0.07, respectively). Infant age at assessment was an inverse predictor (r2 =  
0.31; P = 0.08) of 6 month infant HR. 
3.3.5 Maternal endocannabinoids and infant heart rate: multiple regression  
Significant (P ≤ 0.05) and trending (P ≤ 0.10) multiple regression models describing 
relationships between individual, families, and ratios of maternal endocannabinoids during 
pregnancy and infant HR in the first 6 months of life are presented in Table 3.3. Infant age at 
assessment was included in models at 2 weeks and 6 months as it was a significant or trending 
independent variable in simple linear regression. 
Infant HR at 2 weeks was positively related to maternal AEA:DHEA at 24 gestational 
weeks and infant age at assessment (r2 = 0.89; P ≤ 0.01). Both variables in the model were 
positively related to HR. Maternal n-3 family and AEA at 36 gestational weeks predicted infant 
HR at the 4 month assessment (r2 = 0.62; P = 0.09). There was an inverse relationship for the n-3 
family and a positive relationship was observed for AEA; the variables in the model were both 
independently significant (P ≤ 0.05). Maternal EEA at 20 gestational weeks and infant age at 
assessment were both inversely related to 6 month infant HR (r2 = 0.52; P = 0.05). A model 
including infant age at assessment, maternal EEA, and EPEA at 24 gestational weeks was 
inversely related to infant HR at the 6 month assessment (r2 = 0.82; P ≤ 0.01). Further, maternal 
n-3 family at 32 gestational weeks and infant age at assessment were inversely related to 6 month 
infant HR (r2 = 0.74; P ≤ 0.01). Venous cord EPEA and AEA, with infant age at assessment, 






3.3.6 Maternal endocannabinoids and infant heart rate variability: simple linear regression  
Significant (P ≤ 0.05) simple linear regression models describing relationships between 
individual, families, and ratios of maternal endocannabinoids during pregnancy and infant HRV 
at the 2 week and 6 month assessments are presented in Tables 3.4 and 3.5, respectively. 
 At 24 gestational weeks, maternal AEA:n-3 family was significantly, inversely related to 
infant SDNN at the 2 week assessment (r2 = 0.44; P = 0.05). Similarly, there was an inverse 
Table 3.3 Relationships for maternal n-6 and n-3 endocannabinoids and infant heart rate: multiple 
regression1 
  Heart rate, beats per min 
  2 week assessment 
  Parameters2  Parameter estimates  Model estimates 
Gestational week    β ± SE P  n r2 P 
24 weeks  AEA:DHEA  20.9 ± 9.6    0.07    9 0.89 ≤ 0.01 
  Infant age3  1.6 ± 0.3 ≤ 0.01     
  4 month assessment 
36 weeks  n-3 family  -10.8 ± 4.2    0.05    8 0.62    0.09 
  AEA  24.5 ± 8.6    0.04     
  6 month assessment 
20 weeks  EEA  -104.6 ± 54.8    0.09  11 0.52    0.05 
  Infant age  -0.8 ± 0.3    0.03     
          
24 weeks  EEA  -61.7 ± 24.8    0.05  10 0.82 ≤ 0.01 
  EPEA  -141.5 ± 49.4    0.03     
  Infant age  -0.5 ± 0.2       0.06     
          
32 weeks  n-3 family  -6.2 ± 1.7 ≤ 0.01  11 0.74 ≤ 0.01 
  Infant age  -0.8 ± 0.2 ≤ 0.01     
          
Delivery4  EPEA  -76.1 ± 14.8 ≤ 0.01  11 0.87 ≤ 0.01 
  AEA     -20.5 ± 7.4    0.04     
  Infant age  -0.9 ± 0.2 ≤ 0.01     
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2AEA: ananamide (n-6 related); DHEA: docosahexaenoyl ethanolamine; n-3 family: eicosanoyl ethanolamine (EEA) + 
EPEA: eicosapentaenoyl ethanolamine + DHEA 
3Exact infant age (days) at heart rate variability assessment 
4Venous cord plasma collected at delivery 
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relationship between maternal AEA:DHEA at 24 gestational weeks and SDNN at the 2 week 
assessment (data not shown; r2 = 0.36; P = 0.09). Maternal DHEA and n-3 family at 36  
gestational weeks were significant, positive predictors of 2 week infant SDNN (r2 = 0.37 – 0.38;  
P ≤ 0.05) while there was also a positive association for maternal EEA at 36 gestational weeks 
(data not shown; r2 = 0.30; P = 0.08). 
 
 Predictors of ASDNN at the 2 week assessment were largely similar to those of SDNN. 
Maternal AEA:n-3 family at 24 gestational weeks was inversely related to infant ASDNN at the 
2 week assessment (r2 = 0.58; P = 0.02) and maternal AEA:DHEA was an inverse predictor 
(data not shown; r2 = 0.42; P = 0.06). Maternal EEA and DHEA at 36 gestational weeks were 
positively related to ASDNN at the 2 week assessment (r2 ≥ 0.43; P ≤ 0.02), as was the maternal 
n-3 family (r2 = 0.57; P ≤ 0.01). Further, AEA at 36 gestational weeks was inversely related to 
Table 3.4 Relationships for individual, families, and ratios of maternal n-6 and n-3 
endocannabinoids and infant heart rate variability at 2 weeks: simple linear regression1  
  Infant heart rate variability2,3 
  2 week SDNN, ms 
Gestational week  N β ± SE r2 P 
24 weeks      
     AEA:n-3 family    9     -86.2 ± 37.1 0.44    0.05 
36 weeks      
     DHEA  11      11.7 ± 5.0 0.37    0.05 
     n-3 family  11        9.2 ± 3.9 0.38    0.04 
  2 week ASDNN, ms 
24 weeks      
     AEA:n-3 family    9     -47.6 ± 15.4 0.58    0.02 
36 weeks      
     EEA  11 27.1 ± 10.3 0.43    0.02 
     DHEA  11 7.2 ± 2.2 0.54 ≤ 0.01 
     n-3 family  11 5.8 ± 1.7 0.57 ≤ 0.01 
1Only observations reaching statistical significance (P ≤ 0.05) are reported 
2SDNN: standard deviation of filtered RR intervals over 24-h period; ASDNN: mean of standard deviations of 
filtered RR intervals for all 5 min segments of analysis; SDANN: standard deviation of means of filtered RR 
intervals for all 5 min segments of analysis 
3AEA: anandamide (n-6 related); n-3 family: eicosanoyl ethanolamine (EEA) + (eicosapentaenoyl ethanolamine) 
EPEA + docosahexaenoyl ethanolamine (DHEA) 
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infant ASDNN at the 2 week assessment (data not shown; r2 = 0.46; P = 0.07). There were no 
significant relationships between maternal individual, families, or ratios of n-6 or n-3 
endocannabinoids and infant SDANN at the 2 week assessment.  
There were few significant (P ≤ 0.05) or trending (P ≤ 0.10) n-6 or n-3 endocannabinoid 
predictors of infant HRV (SDNN, ASDNN, and/or SDANN) at the 4 month assessment. For all 
three HRV indices, cord venous EPEA was positively related to 4 month HRV (data not shown; 
r2 ≥ 0.36; P ≤ 0.09), although significant only for SDNN (P = 0.04). For 4 month ASDNN, 
maternal EPEA at 36 gestational weeks was also positively related (data not shown; r2 ≥ 0.38; P 
= 0.08).  
At 24 gestational weeks, maternal AEA, AEA:DHEA, and AEA:n-3 family were all 
inversely related to infant SDNN at the 6 month assessment (r2 ≥ 0.45; P ≤ 0.05). At 32 
gestational weeks, maternal EPEA was the only predictor of 6 month infant SDNN (positive; r2 
= 0.52; P ≤ 0.03). Maternal EEA, EPEA, and DHEA at 36 gestational weeks were independently 
related to infant SDNN (r2 ≥ 0.43; P ≤ 0.05), as was the combined n-3 family (r2 ≥ 0.72; P ≤ 
0.01); all predictors were positive. 
Infant ASDNN at the 6 month assessment was inversely related to maternal AEA:n-3 
family at 24 gestational weeks (r2 ≥ 0.48; P = 0.04). At 32 gestational weeks, maternal EEA and 
the n-3 endocannabinoid family were trending, positive predictors of 6 month ASDNN (data not 
shown; r2 ≥ 0.28; P = 0.09) and maternal EPEA was significant (positive; r2 = 0.77; P ≤ 0.01). 
Maternal EEA, EPEA, DHEA, and the combined n-3 family at 36 gestational weeks were 
positive predictors of infant ASDNN at the 6 month assessment (r2 ≥ 0.53; P ≤ 0.08). There were 
positive, independent associations for venous cord EEA, EPEA, DHEA, and n-3 family with 




Table 3.5 Relationships between individual, families, and ratios of maternal n-6 and n-3 
endocannabinoids and infant heart rate variability at 6 months: simple linear regression1  
  Infant heart rate variability2,3 
  6 month SDNN, ms 
Gestational week  N β ± SE r2 P 
24 weeks      
     AEA    9    -66.0 ± 27.8 0.45    0.05 
     AEA:DHEA    9    -65.5 ±17.4 0.67 ≤ 0.01 
     AEA:n-3 family    9    -88.8 ± 20.1 0.74 ≤ 0.01 
32 weeks      
     EPEA    9     18.0 ± 6.6 0.52    0.03 
36 weeks      
     EEA  11     50.6 ± 15.0 0.56 ≤ 0.01 
     EPEA    9     30.6 ± 13.3 0.43    0.05 
     DHEA  11     13.4 ± 3.0 0.68 ≤ 0.01 
     n-3 family  11     10.7 ± 2.3 0.71 ≤ 0.01 
  6 month ASDNN, ms 
24 weeks      
     AEA:n-3 family    9    -28.1 ± 11.1 0.48    0.04 
32 weeks      
     EPEA    9     10.4 ± 2.2 0.77 ≤ 0.01 
36 weeks      
     EEA  11     22.2 ± 7.0 0.53 ≤ 0.01 
     EPEA  11     19.1 ± 3.8 0.78 ≤ 0.01 
     DHEA  11       6.0 ± 1.4 0.68 ≤ 0.01 
     n-3 family  11       5.1 ± 0.8 0.81 ≤ 0.01 
Delivery4      
     EEA    9   142.1 ± 43.8 0.60 ≤ 0.01 
     EPEA    9     44.6 ± 6.6 0.87 ≤ 0.01 
     DHEA    9     12.8 ± 4.7 0.51    0.03 
     n-3 family    9     11.3 ± 2.7 0.72 ≤ 0.01 
  6 month SDANN, ms 
24 weeks      
     AEA    9    -72.8 ± 27.5 0.50    0.03 
     AEA:DHEA    9    -68.7 ± 18.0 0.68 ≤ 0.01 
     AEA:n-3 family    9    -89.4 ± 22.9 0.69 ≤ 0.01 
36 weeks      
     DHEA  11     12.9 ± 3.4 0.62 ≤ 0.01 
     n-3 family  11     10.1 ± 2.6 0.62 ≤ 0.01 
1Only observations reaching statistical significance (P ≤ 0.05) are reported 
2SDNN: standard deviation of filtered RR intervals over 24-h period; ASDNN: mean of standard deviations of 
filtered RR intervals for all 5 min segments of analysis; SDANN: standard deviation of means of filtered RR 
intervals for all 5 min segments of analysis 
3AEA: anandamide (n-6 related); EPEA: eicosapentaenoyl ethanolamine; DHEA: docosahexaenoyl ethanolamine; 
n-3 family: eicosanoyl ethanolamine (EEA) + EPEA + DHEA 
4Venous cord plasma collected at delivery 
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 Maternal AEA, AEA:DHEA, and AEA:n-3 family at 24 gestational weeks were 
independently, inversely associated with infant SDANN at the 6 month assessment (r2 ≥ 0.50; P 
≤ 0.03). Maternal EPEA at 32 gestational weeks was a positive predictor of 6 month SDANN 
(data not shown; r2 = 0.38; P = 0.08). At 36 gestational weeks, maternal DHEA and n-3 family 
were positive, independent predictors of 6 month SDANN (r2 = 0.62; P ≤ 0.01). There was a 
trend for a positive relationship between maternal AEA:n-3 family at 36 gestational weeks and 
infant SDANN at the 6 month assessment (data not shown; r2 = 0.43; P = 0.08). 
3.3.7 Maternal cytokines, adipokine, and acute phase reactant and infant heart rate and heart rate 
variability: multiple regression  
 
Significant (P ≤ 0.05) multiple regression models describing relationships between 
maternal adiponectin, CRP, and TNF-α during pregnancy and infant HR and HRV are presented 
in Table 3.6. Simple linear regression models are not presented as significant or trending 
variables were also significant in and strengthened by multiple regression modeling.  
 Maternal TNF-α at 24 gestational weeks and exact infant age at assessment were 
positively related to infant HR at the 2 week assessment (r2 = 0.82; P ≤ 0.01); both variables in 
the model were independent predictors (P ≤ 0.05). Infant HR at the 6 month assessment was 
predicted by maternal adiponectin at 20 gestational weeks and infant age at assessment (r2 = 
0.65; P = 0.02). Adiponectin was a positive, significant variable in the model (P = 0.02) while 
age was inverse and trending (P = 0.09). A model including maternal adiponectin, CRP, and 
TNF-α at 20 gestational weeks was related to infant SDNN and SDANN at the 6 month 
assessment (r2 ≥ 0.70; P ≤ 0.03); all variables in the model were inversely related to both HRV 







3.4.1 Infant heart rate and heart rate variability are age-dependent 
With advancing age, infant HR decreased and HRV increased. This was predicted, given 
developmental stage of the population, and is consistent with previous reports (Finley and 
Nugent 1995; Massin and von Bernuth, 1997). In healthy term infants, low HR and high HRV 
indicate accelerated autonomic maturation (Massin and von Bernuth, 1997). Thus, in interpreting 
the current data, maternal circulating factors that are inversely related to HR and/or positively 
related to HRV may have a role in accelerating autonomic development.  
Table 3.6 Relationships for maternal inflammatory biomarkers, infant heart rate, and 
heart rate variability: multiple regression1 
  Parameters2  Parameter estimates  Model estimates 
Gestational week    β ± SE P  n r2 P 
  Infant heart rate, beats per min 
  2 week assessment 
24 weeks  TNF-α  0.9 ± 0.4 0.05  9 0.82  ≤ 0.01 
  Infant age3  2.1 ± 0.4  ≤ 0.01     
  Infant heart rate, beats per min 
  6 month assessment 
20 weeks  Adiponectin  1.2 ± 0.4 0.02  11 0.65    0.02 
  Infant age  -0.5 ± 0.2 0.09     
  Infant SDNN, ms 
  6 month assessment 
20 weeks  Adiponectin  -1.5 ± 0.5 0.03  9 0.85   0.02 
  CRP  -1.1 ± 0.3 0.01     
  TNF-α  -1.3 ± 0.4 0.02     
  Infant SDANN, ms 
  6 month assessment 
20 weeks  Adiponectin  -1.3 ± 0.6 0.07  9 0.70   0.03 
  CRP  -1.0 ± 0.3 0.02     
  TNF-α  -1.4 ± 0.4 0.02     
1Only observations reaching statistical significance (P ≤ 0.05) or trend (P ≤ 0.10) are reported 
2TNF-α: tumor necrosis factor-α; CRP: C-reactive protein 
3Exact infant age (days) at heart rate/heart rate variability assessment 
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3.4.2 Maternal endocannabinoids are associated with infant heart rate and heart rate variability 
To the best of our knowledge, this study is the first to explore and link maternal 
inflammation during pregnancy to infant HR and HRV. Further, this study is the first to assess 
endocannabinoids in relation to HR and HRV in any population. The endocannabinoids related 
to n-6 (AEA) and n-3 (EEA, EPEA, DHEA) fatty acids were of specific interest as the n-6 and n-
3 fatty acid families are metabolically competitive and have contrasting, potent inflammatory 
effects (Calder, 2002; Calder, 2006). Further, the n-6 and n-3 related endocannabinoids 
themselves have divergent roles in modulating inflammation (Yang et al., 2011; Meijerink et al., 
2011) and autonomic function (reviewed by Pertwee, 1997), as discussed below. 
Inflammation-related diseases (i.e., rheumatoid arthritis, coronary heart disease, and 
metabolic syndrome) are characterized by decreased parasympathetic tone and/or HRV (Brunner 
et al., 2002; Hamaad et al., 2005; Goldstein et al., 2007; Bruchfeld et al., 2010). Similarly, in 
otherwise healthy adults, HR increases and HRV reductions are associated with subclinical 
inflammation (Sajadieh et al., 2004).  
Fetal HR and HRV are responsive to maternal nutrition (Gustafson et al., 2013) and 
exercise (May et al., 2010). Maternal inflammation may, in part, underlie these observations. 
Indeed, dietary fatty acid intake (Wood et al., 2010; Balvers et al., 2012; Hansen, 2013; 
Meijerink et al., 2013) and exercise (reviewed by Tantimonaco et al., 2014) modulate the 
endocannabinoid system, supporting this hypothesis.  
We cannot, with certainty, state that anti- and pro-inflammatory properties of 
endocannabinoids underlie our observations. Endocannabinoids have several biological roles in 
vivo, making it difficult to pinpoint causality. Further, endocannabinoid concentrations reflect 
those of their respective fatty acid precursors. Dietary n-3 LCPUFA shifts n-3/n-6 fatty acid 
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balance of membrane lipids, resulting in compensatory increases in n-3 endocannabinoids, EPEA 
and DHEA, and reduced production of AEA (Wood et al., 2010). Beneficial cardiovascular 
effects of n-3 LCUPFA are well-documented, although the mechanism(s) of action have not been 
elucidated (reviewed in Jung et al., 2008; Adkins and Kelly, 2010). Thus, our observations may 
be a consequence of effects mediated by fatty acids from which the endocannabinoids were 
derived. However, given the central role of inflammation in chronic diseases, especially those of 
cardiovascular significance, and similar influences of n-3 LCPUFA and n-3 related 
endocannabinoids on inflammatory processes, it is plausible that endocannabinoids may 
partially: 1) explain underlying mechanisms and 2) be responsible for benefits associated with n-
3 LCPUFA and inflammation (Wainwright and Michel, 2013).  
Endocannabinoids bind CB1 and CB2 receptors (Yang et al., 2011; Anagnostopoulos et 
al., 2010) with AEA preferentially binding CB1 and DHEA having a greater affinity for CB2 
receptors in human inflammatory cells (Yang et al., 2011). CB1 receptors have been implicated 
in pro-inflammatory chemokine secretion (Gaffal et al., 2013) while CB2 receptor activation 
inhibits release of inflammatory mediators associated with pain (Ibrahim et al., 2003). Further, 
DHEA exerts potent anti-inflammatory effects in LPS-stimulated RAW246.7 macrophages 
(Meijerink et al., 2011).  
AEA downregulates autonomic function (reviewed by Pertwee, 1997). Activation of 
prejunctional or presynaptic CB1 receptors by AEA inhibits acetylcholine release (ACh) by the 
parasympathetic nervous system (Coutts and Pertwee, 1996; Gifford and Ashby, 1996) and 
norepinephrine release by the sympathetic nervous system (Ishac et al., 1996). Inhibition of ACh 
release suppresses parasympathetic tone and, thus, HRV. 
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 Our data support conclusions that can be drawn from the above discussion, that n-3 
endocannabinoids displace their n-6 counterparts and dampen pro-inflammatory processes, 
reducing HR and increasing HRV. Using simple linear and multiple regression analysis, we 
consistently observed that individual n-3 endocannabinoids and the combined n-3 
endocannabinoid family (EEA + EPEA + DHEA) in maternal and/or venous cord plasma are 
associated with reduced infant HR and increased HRV. Conversely, our data indicate an 
association between maternal AEA, increased infant HR, and reduced HRV. The ratio of 
maternal AEA:n-3 family and AEA:DHEA also had predictive value such that shifts favoring 
AEA were related to increased infant HR and reduced HRV. We observed an inverse 
relationship between venous cord AEA and infant HR at the 6 month assessment; this was the 
only beneficial association for AEA. Venous cord EPEA was also a significant, inverse predictor 
of 6 month infant HR, however, to a much greater extent. Compared AEA, an increase of equal 
amounts of venous cord plasma EPEA was predicted to result in an approximate 3.7-fold 
reduction in HR. Thus, while these data indicate cord AEA may be associated with accelerated 
HR development, they also point to EPEA as a more potent agent.  
3.4.3 Maternal cytokines, adipokines, and acute phase reactants in relation to infant heart rate 
and heart rate variability: further investigation needed 
 
In the current study, we observed few significant relationships between maternal cytokine 
(TNF-α, IL-6), adipokine (adiponectin), or acute phase reactant (CRP) concentrations and infant 
HR and HRV during the first 6 months of life. We hypothesize this is dually due to sample size 
and low- to moderate-detection of biomarkers in maternal and venous cord serum. IL-6 was not 
included in statistical analyses for any timepoint excepting delivery (venous cord serum) due to 
marginal detectability. As such, many regression models in the current study were limited to <11 
women-infant pairs.  
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In the current study, significant multiple regression models were specific to inflammatory 
biomarkers at earlier timepoints during pregnancy (20 and 24 gestational weeks). The driving 
force behind this observation is unclear, but may reflect direct interactions between 
inflammatory biomarkers and the sympathetic nervous system as parasympathetic influence 
emerges around 30 – 32 gestational weeks (Sachis et al., 1982). This observation may also be 
coincidental and a result of sample size limitations.  
Parasympathetic activity and/or HRV are consistently, inversely associated with CRP 
(Kon et al., 2006; Lanza et al., 2006; Psychari et al. 2007) and TNF-α (Malave et al., 2003; 
Marsland, et al., 2007). Our data are in line with these observations, as CRP and TNF-α were 
both inverse predictors of HRV in multiple regression models.  
Associations between adiponectin, HR, and HRV have been explored (Wakabayashi and 
Aso, 2004; Takahashi et al., 2007; Piestrzeniewicz et al., 2008), albeit, not as extensively as for 
CRP and TNF-α. There were no associations between adiponectin and frequency- or time-
domain HRV indices in males with acute myocardial infarction (Piestrzeniewicz et al., 2008). 
However, low serum adiponectin in type 2 diabetes was associated with sympathetic 
hyperactivity (Wakabayashi and Aso, 2004; Takahashi et al., 2007), which would be clinically 
apparent as increased HR and reduced HRV. In the current study, maternal adiponectin was a 
positive and inverse predictor of infant HR and time-domain indices of HRV, respectively. The 
disconnect between our observations and those of previous studies may reflect the population 
assessed. Pregnancy is characterized by a physiological increase in insulin resistance that ensures 
nutrient delivery to the developing fetus. In the non-pregnant state, adiponectin concentrations 
negatively correlate with insulin sensitivity (Hotta et al., 2000; Weyer et al., 2001). However, in 
a population similar to the current study (pregnant women free of gestational, type 1, or type 2 
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diabetes), adiponectin concentrations did not differ across trimesters (Mazaki-Tovi et al., 2007) 
despite assumed progressive decreases in insulin sensitivity. These observations suggest 
adiponectin regulation may be altered during pregnancy and may explain the inconsistencies 
between previous observations (Wakabayashi and Aso, 2004; Takahashi et al., 2007; 
Piestrzeniewicz et al., 2008) and findings of the current study. 
3.5 Limitations 
This study was limited primarily by sample size (n = 11). Much of the presented data 
existed as statistical trends However, many relationships were highly significant and consistently 
observed, especially with regard to n-3 related endocannabinoids. Further, sample size limited 
inclusion of factors other than maternal inflammatory biomarkers and infant age at HR/HRV 
assessment in multiple regression models due to loss of statistical power. To address this, 
participants were required to meet strict inclusion and exclusion criteria, defined above, for study 
enrollment. These criteria ensured the study participants (mothers) had similar characteristics to 
minimize the influence of external factors on study outcomes.  
3.6 Conclusion 
Alterations in maternal inflammatory status may be the common mechanism underlying 
the previously observed effects of maternal nutrition and exercise on fetal HR and HRV (May et 
al., 2010; Gustafson et al., 2013), as supported by the current study. We have provided 
compelling data evidencing an association between maternal endocannabinoids during 
pregnancy with infant HR and HRV. Although we are unable to definitively conclude these 
observations are a direct consequence of anti-inflammatory actions of n-3 endocannabinoids, we 
provide a discussion supporting this hypothesis and call for future studies to include assessments 
of these novel bioactive fatty acid derivatives. Due to study limitations, we cannot conclusively 
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provide a link between maternal concentrations of adiponectin, CRP, TNF-α, and IL-6 during 
pregnancy and infant HR and HRV. However, these inflammatory biomarkers are worthy of 
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APPENDIX B. CONTINUING IRB APPROVAL FOR THE LAMBS STUDY AT 






























































































































































































APPENDIX E. CHROMATOGRAM LABELED WITH REFERENCE TO STANDARD 















































APPENDIX E. CHROMATOGRAM LABELED WITH REFERENCE TO STANDARD 





















































































Each analyte’s single reaction monitoring transition is listed followed by the specific collision 
energy in brackets. EPEA: eicosapentaenoyl ethanolamide, C22H35NO2; AEA: arachidonyl 
ethanolamide, C22H32O2; DHEA: docosahexaenoyl ethanolamide, C24H37NO2; EEA: eicoseneoyl 
ethanolamide, C22H43NO2  
 
Williams J, Wood J, Pandarinathan L, et al. Quantitative method for the profiling of the 







APPENDIX G. CHROMATOGRAMS OF EXTRACTED ENDOCANNABINOID 





































Arrow indicates analytes analyzed by Northeastern University for the current study. EPEA: 
eicosapentaenoyl ethanolamide, C22H35NO2; AEA: arachidonyl ethanolamide, C22H32O2; DHEA: 
docosahexaenoyl ethanolamide, C24H37NO2; EEA: eicoseneoyl ethanolamide, C22H43NO2  
 
Williams J, Wood J, Pandarinathan L, et al. Quantitative method for the profiling of the 




APPENDIX H. CHROMATOGRAMS OF NORMALIZED, EXTRACTED 





































Arrow indicates analytes analyzed by Northeastern University for the current study. EPEA: 
eicosapentaenoyl ethanolamide, C22H35NO2; AEA: arachidonyl ethanolamide, C22H32O2; DHEA: 
docosahexaenoyl ethanolamide, C24H37NO2; EEA: eicoseneoyl ethanolamide, C22H43NO2  
 
Williams J, Wood J, Pandarinathan L, et al. Quantitative method for the profiling of the 




APPENDIX I. CHROMATOGRAMS OF DEUTERATED INTERNAL STANDARDS 










































EPEA: eicosapentaenoyl ethanolamide, C22H35NO2; AEA: arachidonyl ethanolamide, C22H32O2; 
DHEA: docosahexaenoyl ethanolamide, C24H37NO2; EEA: eicoseneoyl ethanolamide, 
C22H43NO2. d4- indicates deuterated analyte. 
RT: 0.00 - 13.00
































































































TIC F: + c APCI SRM 
ms2 346.220 
[62.030-62.330]  MS  
ICIS 33
NL: 1.51E4
TIC F: + c APCI SRM 
ms2 350.240 
[66.030-66.330]  MS  
ICIS 33
NL: 1.48E6
TIC F: + c APCI SRM 
ms2 354.270 
[62.030-62.330]  MS  
ICIS 33
NL: 1.59E5
TIC F: + c APCI SRM 
ms2 358.280 
[66.050-66.350]  MS  
ICIS 33
NL: 3.28E6
TIC F: + c APCI SRM 
ms2 379.240 
[287.060-287.360]  
MS  ICIS 33
NL: 2.46E5
TIC F: + c APCI SRM 
ms2 384.260 
[287.060-287.360]  
MS  ICIS 33
NL: 8.16E5
TIC F: + c APCI SRM 
ms2 331.240 
[313.150-313.450]  
MS  ICIS 33
NL: 1.14E5
TIC F: + c APCI SRM 
ms2 336.250 
[318.140-318.440]  
MS  ICIS 33
RT: 0.00 - 13.00














































































TIC F: + c APCI SRM 
ms2 348.250 
[62.010-62.310]  MS 
 ICIS 33
NL: 4.56E4
TIC F: + c APCI SRM 
ms2 352.250 
[66.050-66.350]  MS 
 ICIS 33
NL: 2.26E6
TIC F: + c APCI SRM 
ms2 300.250 
[62.010-62.310]  MS 
 ICIS 33
NL: 2.28E5
TIC F: + c APCI SRM 
ms2 304.230 
[66.050-66.350]  MS 
 ICIS 33
NL: 6.28E5
TIC F: + c APCI SRM 
ms2 326.230 
[62.010-62.310]  MS 
 ICIS 33
NL: 6.27E4
TIC F: + c APCI SRM 
ms2 330.250 
[66.040-66.340]  MS 
 ICIS 33
NL: 1.40E5
TIC F: + c APCI SRM 
ms2 372.290 
[62.030-62.330]  MS 
 ICIS 33
NL: 1.98E4
TIC F: + c APCI SRM 
ms2 376.260 
[66.030-66.330]  MS 
 ICIS 33
RT: 0.00 - 13.00














































































TIC F: + c APCI SRM 
ms2 348.250 
[62.010-62.310]  MS 
 ICIS 33
NL: 4.56E4
TIC F: + c APCI SRM 
ms2 352.250 
[66.050-66.350]  MS 
 ICIS 33
NL: 2.26E6
TIC F: + c APCI SRM 
ms2 300. 50 
[62.010-62. 10]  MS 
 CIS 33
NL: 2.28E5
TIC F: + c APCI SRM 
ms2 3 4.230 
[ 6.050- 6. 50]  MS 
 CIS 33
NL: 6.28E5
TIC F: + c APCI SRM 
ms2 326.230 
[62.010-62. 10]  MS 
 ICIS 33
NL: 6.27E4
TIC F: + c APCI SRM 
ms2 330.250 
[ 6.040- 6.340]  MS 
 ICIS 33
NL: 1.40E5
TIC F: + c APCI SRM 
ms2 37 .290 
[62. 3 62.3 0]  MS 
 ICIS 33
NL: 1.98E4
TIC F: + c APCI SRM 
ms2 376.260 












APPENDIX J. CHROMATOGRAMS OF DEUTERATED INTERNAL STANDARDS 










































EPEA: eicosapentaenoyl ethanolamide, C22H35NO2; AEA: arachidonyl ethanolamide, C22H32O2; 
DHEA: docosahexaenoyl ethanolamide, C24H37NO2; EEA: eicoseneoyl ethanolamide, 
C22H43NO2. d4- indicates deuterated analyte 
RT: 0.00 - 13.00











































































































TIC F: + c APCI SRM 
ms2 348.250 
[62.010-62.310]  MS 
 ICIS 92
NL: 5.28E4
TIC F: + c APCI SRM 
ms2 352.250 
[66.050-66.350]  MS 
 ICIS 92
NL: 2.53E4
TIC F: + c APCI SRM 
ms2 300.250 
[62.010-62.310]  MS 
 ICIS 92
NL: 2.53E5
TIC F: + c APCI SRM 
ms2 304.230 
[66.050-66.350]  MS 
 ICIS 92
NL: 4.58E3
TIC F: + c APCI SRM 
ms2 326.230 
[62.010-62.310]  MS 
 ICIS 92
NL: 6.78E4
TIC F: + c APCI SRM 
ms2 330.250 
[66.040-66.340]  MS 
 ICIS 92
NL: 7.24E2
TIC F: + c APCI SRM 
ms2 372.290 
[62.030-62.330]  MS 
 ICIS 92
NL: 2.23E4
TIC F: + c APCI SRM 
ms2 376.260 
[66.030-66.330]  MS 
 ICIS 92
RT: 0.00 - 13.00











































































































TIC F: + c APCI SRM 
ms2 348.250 
[62.010-62.310]  MS 
 ICIS 92
NL: 5.28E4
TIC F: + c APCI SRM 
ms2 352.250 
[66.050-66.350]  MS 
 ICIS 92
NL: 2.53E4
TIC F: + c APCI SRM 
ms2 300.250 
[62.010-62.310]  MS 
 ICIS 92
NL: 2.53E5
TIC F: + c APCI SRM 
ms2 304.230 
[66.050-66.350]  MS 
 ICIS 92
NL: 4.58E3
TIC F: + c APCI SRM 
ms2 326.230 
[62.010-62.310]  MS 
 ICIS 92
NL: 6.78E4
TIC F: + c APCI SRM 
ms2 330.250 
[66.040-66.340]  MS 
 ICIS 92
NL: 7.24E2
TIC F: + c APCI SRM 
ms2 372.290 
[62.030-62.330]  MS 
 ICIS 92
NL: 2.23E4
TIC F: + c APCI SRM 
ms2 376.260 
[66.030-66.330]  MS 
 ICIS 92
RT: 0.00 - 13.00




























































































































TIC F: + c APCI SRM 
ms2 346.220 
[62.030-62.330]  MS  
ICIS 92
NL: 1.65E4
TIC F: + c APCI SRM 
ms2 350.240 
[66.030-66.330]  MS  
ICIS 92
NL: 4.70E2
TIC F: + c APCI SRM 
ms2 354.270 
[62.030-62.330]  MS  
ICIS 92
NL: 1.95E5
TIC F: + c APCI SRM 
ms2 358.280 
[66.050-66.350]  MS  
ICIS 92
NL: 4.53E5
TIC F: + c APCI SRM 
ms2 379.240 
[287.060-287.360]  
MS  ICIS 92
NL: 2.28E5
TIC F: + c APCI SRM 
ms2 384.260 
[287.060-287.360]  
M   ICIS 92
NL: 4.55E5
TIC F: + c APCI SRM 
ms2 331.240 
[313.150-313.450]  
MS  ICIS 92
NL: 1.28E5
TIC F: + c APCI SRM 
ms2 336.250 
[318.140-318.440]  
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